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Abstract 
 For 133 years, institutionalization was the primary model of care provided for individuals 
with intellectual disabilities in Ontario. By March 31, 2009, the last remaining institution in 
Ontario was closed. Given that individuals with intellectual disabilities are more likely to 
develop health and mental health comorbidities than the general population, investigating 
outcomes after relocation is critical for ensuring safe and successful transitions to community 
settings. This study examined changes in psychotropic medication usage following 
deinstitutionalization as well as changes over time in the community. Various proxy measures 
were collected on demographic variables (e.g., age, sex, etc.), adaptive functioning, challenging 
behaviour, psychotropic medication usage, health status, and mental health status. A multilevel 
model was used to investigate within and between-person changes in psychotropic medication 
usage longitudinally across three points in time. Variables, including adaptive functioning, 
challenging behaviour, and health and mental health status, were investigated as potential 
predictors of psychotropic medication usage. Health variables and mental health status positively 
predicted psychotropic medication. Cognitive performance and health instability from the facility 
to the community had a negative influence on the total number of psychotropic medications. 
Challenging behaviour did not predict psychotropic medication usage in this study, possibly due 
to the measure used. Further examination of these results may be used to inform policy and 
practice for individuals with intellectual disabilities in Ontario. 
Keyword(s): Deinstitutionalization, intellectual disabilities, psychotropic medication, 
polypharmacy, longitudinal 
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Introduction 
 On March 31, 2019, the last three remaining institutions in Ontario were closed. After the 
closing of the institutions, the Facilities Initiative (FI) studies were conducted to evaluate the 
well-being of individuals with intellectual disabilities (ID) after moving to community settings. 
These studies examined the impact of deinstitutionalization on former residents who transitioned 
to community settings. 
There were four components in the FI studies including; the Quasi-Longitudinal (QL) 
study (Condillac, Frijters, & Martin, 2012); a survey of the perspectives of the community 
agencies (Griffiths, Owen, & Condillac, 2015), a survey of family member feedback following 
deinstitutionalization (Griffiths, Owen, & Condillac, 2015); and a focus group/interview study on 
the perceptions of the deinstitutionalization process for families, former residents, agencies, 
behavioural consultants, and planners (Owen, Griffiths, & Condillac, 2015). In the QL study, the 
authors found that overall, the majority of former residents were faring the same or better in the 
community since relocating from the facilities. In particular, former residents experienced 
improvements across cognitive capacity (CPS) and both perceived ability and current 
performance of daily living activities (IADLs). Although there were increases in anhedonia and 
depression symptoms, the individuals who were experiencing difficulties in the community at the 
first community visit, appeared to have been more well-adjusted by the second community visit 
(Condillac et al., 2012). These findings aligned with reports from other deinstitutionalization 
outcome studies and overall, support integrated community-living as having improved the 
quality of lives of individuals with ID (Hamelin, Frijters, & Griffiths, 2011; Lemay, 2009; Kim, 
Larson, & Larkin, 2001).  
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In 2012, Rahim conducted further analyses for the QL study that focused on psychotropic 
medication patterns before and after deinstitutionalization among the same group of individuals 
in the QL study (Condillac et al., 2012). A significant increase in the number of antidepressant 
and antipsychotic medications was reported after relocation to community settings. These 
findings contradicted other studies that found either a decrease in psychotropic medication 
(McGillivray & McCabe, 2005) or no change following deinstitutionalization (Nottestad & 
Linaker, 2003). The mixed results emphasized the need for additional research to be conducted 
that examines psychotropic medication among individuals who experienced 
deinstitutionalization.  
The current study was conducted to further analyze medication usage from the QL study 
and evaluated psychotropic medication usage among the same group of individuals who 
relocated to community settings in Ontario (Condillac et al., 2012; Rahim, 2012). This study 
differed from Rahim (2012) in that it examined changes across three points in time (facility, 
community, and community follow up) and the investigation of potential predictors of 
psychotropic medication use. Understanding changes over time in the community is critical for 
evaluating the extent to which individuals with ID are living improved lives in the community, 
and many deinstitutionalization studies lacked this component of analysis (McGillivray & 
McCabe, 2005; Nottestad & Linaker, 2003). Secondly, examining predictors of psychotropic 
medication usage can lead to a better understanding of risk factors for polypharmacy and 
psychotropic medication use among individuals who relocated to community settings in Ontario 
and may provide insights to inform treatment planning and service delivery. 
The purpose of this study is to contribute to and inform the field of research examining 
psychotropic medication usage among individuals with ID who experienced 
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deinstitutionalization. This study may increase the awareness of the overreliance on psychotropic 
medications used to treat individuals with ID despite the lack of consistent evidence to suggest 
their efficacy (Lunsky et al., 2017; O’Dwyer, McCallion, McCarron, & Henman, 2018). 
Understanding specific relationships between individual characteristics and psychotropic 
medication usage may help medical and mental health professionals increase their sensitivity to 
risk factors for polypharmacy and could potentially influence prescribing practices away from 
overmedicating people with ID. These findings could be used to inform regulatory bodies and 
organizations that have created and are responsible for revising psychotropic medication 
guidelines for individuals with ID. 
Literature Review 
History of Institutionalization 
For over a century, institutionalization was the primary method for caring for individuals 
with an intellectual disability in Ontario (Brown & Radford, 2015). For this study, ID refers to 
individuals who experienced limitations before the age of 18 that manifest as motor, social, 
cognitive, or language impairments (Maulik, Mascenrenhas, Mathers, Dua, & Saxena, 2011). 
Participants from studies that used the outdated terminology “mental retardation” or the preferred 
term in the UK, learning disability, will be referred to as having an intellectual disability. This 
section reviews the history of institutionalization in North America. 
Within the early industrial and agricultural societies in the nineteenth and early twentieth 
century, individuals with impairments worked within the community or with their families 
(Cameron, 2014; Oliver & Barnes, 2012). During this time, the contribution of individuals with 
impairments was recognized. However, as industrialization developed, the notion of an ideal 
employee emerged, which resulted in individuals with impairments struggling to find 
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employment (Cameron, 2014). Institutions arose as school settings to train individuals with ID to 
become adult workers (Trent, 1994). Although the initial intent was to train individuals, the 
purpose of institutions ultimately became to segregate this group of individuals from others 
(Griffiths, Owen, & Condillac, 2017).  
Walmsley (2006) emphasized that the growth of institutions from 1900 to 1950 occurred 
for two reasons: protecting society from the perceived negative influence of individuals with ID, 
and for concealing persons with ID from the harmful effects of society. In particular, eugenics 
emerged as a societal belief throughout the late nineteenth and early twentieth century (Davis, 
2014). This devastating ideology led to the belief that individuals with ID were best supported 
through an institutional setting in which their lives, including reproduction, could be controlled 
(Griffiths et al., 2017; Senn & The G. Allan Roeher Institute, 1996; Trent, 1994). In addition to 
the influence of eugenics, the medical model of disability contributed to the number of 
individuals living in institutions.  
Although institutions were intended to focus on care, training, safety and rehabilitation, 
limitations also arose due to the medical model of care being applied to disability. At that time, 
the perspective of professionals in the field was that disability should be treated as a medical 
issue (Griffiths et al., 2017). Since ID was viewed as a medical condition, families believed that 
individuals with ID required constant professional care (Brown & Radford, 2015; Cameron, 
2014). This medical model of disability was further supported by the fact that individuals grew 
old in the institutions, thereby suggesting that a diagnosis of ID was permanent and untreatable 
(Brown & Radford, 2015). As such, a medical model approach that was viable for segregation 
and control of individuals with ID developed over time and resulted in widespread 
institutionalization (Griffiths et al., 2017). Through the 50s and early 60s, a shifting perspective 
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from the nonmedical view of ID developed not only due to shifts in ideology but also due to 
devoted advocacy groups (Brown & Percy, 2007).  
Deinstitutionalization 
The deinstitutionalization movement included two objectives: emphasizing a community 
living ideology for individuals with ID and transitioning individuals to residential-based homes 
(Griffiths et al., 2017). The paradigm shift from the medical model of disability to 
deinstitutionalization was largely moved forward due to families of individuals with ID 
promoting the principles of normalization, which states that persons with ID should have access 
to a typical life (e.g., choices and desires that are respected and considered, financial privileges, 
and security measures; Nirje, 1969). The negative publicity described by Blatt et al. (1980) also 
provided the support that relocation to community settings would improve the quality of life of 
individuals with ID. 
 Institutions received negative publicity regarding allegations of abuse, loss of personal 
security, punishment, and conditions and lack of positive outcomes (Blatt, 1980). These concerns 
were publicized by Blatt and Kaplan in 1966, who exposed the extent to which institutions were 
not providing adequate care for individuals with ID. These findings eventually led to institutional 
reform. In particular, institutions became smaller and better supervised from the 1970s to 1990s 
with increased staffing (Griffiths et al., 2017). In Ontario, by the mid-1970s, 16 institutions were 
open, and over 10,000 people with ID were receiving residential care in these institutions (Martin 
& Ashworth, 2010). However, Canada began closing and downsizing institutions as support for 
community-based living settings for individuals with ID emerged. Despite these changes in sizes 
and crowding of institutions, when Blatt (1980) examined the changes in the institutions in the 
US 15 years later, concerns remained. Although progress was made in terms of increased 
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staffing, more funding, and less crowding, the authoritarian treatment of the residents remained 
(Blatt; 1980; Taylor & Bogdan, 1992). Blatt (1980) concluded that closing institutions and 
promoting community integration would help resolve these concerning attitudes towards 
individuals with ID. 
The continued trends towards deinstitutionalization in the 1980s may be seen by the 
enactment of various plans and acts by the Ontario government. Following the initial downsizing 
and closing of institutions in the 1970s, Bill 82 was enacted in 1980, which required that children 
with disabilities remain in the public-school system (Brown & Radford, 2015). In 1983, the Five-
Year Plan was implemented by the Ontario government, which set closure dates for various 
institutions across Ontario (Brown & Radford, 2015). Lastly, in 2004, the Ministry of 
Community and Social Services (MCSS) announced that the three remaining institutions (i.e., 
Huronia Regional Centre, Rideau Regional Centre, and Southwest Regional Centre) would be 
closed by 2009. By March 31, 2009, the final institution in Ontario was closed. The 
deinstitutionalization trends observed in Ontario, Canada also aligned with the policies of other 
nations, including the United States, England, and Australia (Lemay, 2009). 
Deinstitutionalization Outcomes 
Institutions were considered to provide comprehensive care supporting all aspects of 
personal health and well-being. Researchers studying the outcomes of deinstitutionalization have 
sought to determine the degree to which individuals’ outcomes and access to supports and 
services were the same, better, or worse than they had been in the facilities. There have been 
multiple studies that have examined a specific group of individuals who transitioned to 
community (e.g., Condillac et al., 2012; Nottestad & Linaker, 1999) as well as meta-analyses 
that have evaluated deinstitutionalization outcomes across several studies (e.g., Hamelin et al., 
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2011; Lemay, 2009; Kim et al., 2001). Outcomes that have been examined include quality of life, 
family contact and involvement, adaptive behaviour and daily living activities, cognitive 
functioning, health, mental health, and psychotropic medication use. 
Quality of life. Most studies reported improvements in quality of life (QoL) after 
participants transitioned to the community (e.g., Condillac et al., 2012; Lemay, 2009; Nottestad 
& Linaker, 1999; Nottestad & Linaker, 2003; Kim et al., 2001). In 2012, Condillac et al. 
examined QoL using the Other Person Interview developed by Raphael, Brown and Renwick 
(1996). The measure was designed to estimate the quality of life for people with ID who may not 
have the skills to respond to an interview. In the QL study, administration of the measure was by 
proxy with a staff person who knew the person well and was active in his or her day-to-day life. 
During the first community visit, mean QoL indicators fell within the adequate range (i.e., might 
need improvement) suggesting that some individuals had optimal QoL, while others experienced 
adequate or suboptimal QoL. However, during the second community visit, a significant increase 
in QoL was noted with many more individuals experiencing optimal QoL, and the distribution of 
scores approximating previous findings for individuals in community settings in Ontario. This 
significant increase suggested an improvement in life quality over time, with further adjustment 
to the community. Similarly, Lemay (2009) reported that deinstitutionalization resulted in 
increases in QoL. However, community settings could be improved. Nottestad and Linaker 
(1999; 2003) also reported improvements in living conditions, as well as increases in perceived 
QoL when participants moved the community. As such, most individuals with ID transitioning 
from institutions to community living experienced gains in perceived QoL in the community.  
Family contact and involvement. The changes observed in the levels of family contact 
due to deinstitutionalization were mixed across North America deinstitutionalization studies 
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(Condillac et al., 2012; Spreat & Conroy, 2002). Spreat and Conroy (2002) determined that 
family contact often increased after the individuals were living in the community and that these 
changes were maintained for up to four years (Spreat & Conroy, 2002). In 2015, Owen, Griffiths, 
and Condillac reported the findings from two of the FI studies. Overall, the authors found that 
the reports from the families were positive. In the final report of the QL study, Condillac et al. 
(2012) examined family involvement before and after community placements and found that 
44.3% of the participants were doing better in terms of family contact. The authors reported that 
50% had the same amount of family contact since relocating. Only 5.7% of the participants were 
doing worse in that they had not seen their family within the last month. Therefore, most North 
American studies reported improvements in family contact and involvement following relocation 
to community settings.  
Adaptive behaviour and daily living activities. In the QL study, Condillac et al. (2012) 
reported that individuals with ID improved in the performance of self-care and instrumental 
activities after deinstitutionalization. These improvements in adaptive skills were consistent with 
previous studies that evaluated adaptive function in individuals with ID who had transitioned to 
community placements (Hamelin et al., 2011; Kim et al., 2001; Lemay, 2009). Hamelin et al. 
(2011) conducted a meta-analysis of studies evaluating adaptive behaviour outcomes after 
deinstitutionalization. Overall, studies that qualified for the meta-analysis (N = 48) demonstrated 
that there were gains across 75% of adaptive behaviour domains. The individuals who achieved 
the greatest gains in adaptive functioning had transitioned to group home settings, rather than 
cluster homes or intermediate care centres. Similarly, Kim et al. (2001) conducted a meta-
analysis of studies that examined adaptive functioning as a deinstitutionalization outcome. 
Thirteen of 22 studies were found to have significant increases in adaptive behaviour skills 
PSYCHOTROPIC MEDICATION PATTERNS  9 
following relocation. These findings suggested that, overall, most individuals who moved to 
community settings were reported to have made significant gains in adaptive functioning after 
transitioning to the community.  
Cognitive functioning. After individuals with ID in Ontario transitioned to community 
living, there were cognitive functioning improvements observed across most individuals 
(Condillac et al., 2012). Given that the Cognitive Performance Scale (CPS) included a decision-
making item, changes in cognitive functioning were partially explained by the increased 
emphasis on choice-making in the community compared with the custodial care model in some 
of the facilities (Condillac et al., 2012). Lemay (2009) conducted a meta-analysis of 
deinstitutionalization studies in Canada. Lemay (2009) determined that individuals with severe 
cognitive deficits experienced adaptive functioning improvements as well. Young, Ashman, 
Sigafoos, and Grevell (2000; 2001) reported on deinstitutionalization outcomes in Australia. 
Similarly, the authors reported significant improvements in adaptive behaviours, such as choice-
making, following deinstitutionalization. These findings aligned with the increases in choice-
making and cognitive functioning found in the QL study (Condillac et al., 2012). 
Health. In the QL study, medical symptoms increased across pain, bladder management, 
and health stability (Condillac et al., 2012). These specific changes may have been related to the 
significant portion of the sample who were aging and/or to changes in staff across settings. Other 
physical health conditions associated with aging may have contributed to the increases observed 
in pain management as well as community staff training for recognizing and managing pain in 
individuals with ID, particularly non-verbal individuals. Similarly, Lemay (2009) hypothesized 
that mortality rates increasing following deinstitutionalization might have occurred due to 
individuals becoming more susceptible to mortality after experiencing major life changes. 
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Lerman, Apgar, and Jordan (2003) examined deinstitutionalization and mortality among 150 
“movers” and 150 “stayers” in New Jersey. The authors analyzed risk factors for all deaths using 
a logistic regression. Age, low self-care, medical conditions, and epilepsy/seizure disorders 
predicted deaths. However, adding whether the individual stayed or moved did not change the 
model. Therefore, deinstitutionalization did not impact mortality in this group of individuals. 
Overall, although some studies indicated minor changes related to health, these changes may 
have been anticipated, as these populations were aging and experiencing major life changes 
through the process of relocation.  
Mental health. In the QL study, Condillac et al. (2012) noted that most individuals with 
ID experienced the same or improved levels of psychiatric symptoms. Nonetheless, some 
individuals experienced increased levels of anhedonia (i.e., loss of pleasure) and or depression 
symptoms. However, these symptoms improved over time in the community. The individuals 
who experienced the greatest increases in depression and anhedonia were older individuals who 
had lived in the institutions for longer amounts of time. Condillac et al. (2012) emphasized that 
changes in anhedonia and depression symptoms may have emerged due to the large number of 
changes associated with transitioning (e.g., loss of contact with friends, family, and staff, and 
changes in living arrangements, etc.). Nottestad and Linaker (1999) also examined the 
psychiatric health care needs of individuals who transitioned from institutions to the facilities in 
Norway. The authors found no significant changes in psychiatric health problems when 
participants transitioned to the community. Nottestad and Linaker (2003) also determined that 
there were no changes in the proportion of individuals diagnosed with anxiety or schizophrenia 
across settings, demonstrating that these diagnoses persisted after individuals relocated to 
community settings. The results of these studies indicated that transitioning to the community 
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may be related to initial increases in some mental health symptoms, such as depression and 
anhedonia symptoms, but did not impact psychiatric diagnoses overall. However, these 
symptoms appeared to decrease over time in the community.  
Challenging behaviour. Reports on challenging behaviour (CB) following 
deinstitutionalization were mixed across studies. In the QL study, most individuals demonstrated 
the same or lower levels of CB after transitioning to the community (Condillac et al., 2012). 
However, the authors reported increases in self-injurious and sexually inappropriate behaviours 
in some individuals after transitioning to the community. The authors hypothesized that these 
increases in CB might have been responses to individuals having difficulty with transitioning and 
communicating this distress. They also suggested that the increases in sexually inappropriate 
behaviour could have been related to community expectations rather than individual behaviour. 
For instance, some behaviours (e.g., undressing before arriving in the bathroom) may have been 
acceptable in facility settings but problematic in the community settings. Nottestad and Linaker 
(1999) also determined that former residents experienced higher levels of CB after relocation to 
community settings. Kim et al. (2001) conducted a meta-analysis of deinstitutionalization studies 
in the US and found that ten studies reported a reduction in CB, while eight studies indicated 
increases in CB. These results emphasized the fact that the reports regarding CB after 
deinstitutionalization varied across studies.  
Psychotropic medication. There have been mixed reports regarding changes in 
psychotropic medication following deinstitutionalization (e.g., Condillac et al., 2012; 
McGillivray & McCabe, 2005; Nottestad & Linaker, 2003; Rahim, 2012). Rahim (2012) 
examined psychotropic medication patterns among the group of individuals who experienced 
deinstitutionalization in Ontario. The results demonstrated a significant increase in psychotropic 
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medications, specifically antidepressants and antipsychotic medications when participants 
transitioned to the community. In 2005, McGillivray and McCabe examined the influence of 
residence (e.g., institutions, community, respite care, and other) on psychotropic medication 
among individuals with ID in 1993 and 2000. The authors reported that in 1993, medication 
usage was greater among persons living in institutions. Further, in 2000, facility residents 
experienced more polypharmacy than individuals living in community settings. However, in 
2000, the proportion of psychotropic medication prescriptions relative to the population was the 
same across facility and community settings. Similarly, Nottestad and Linaker (2003) reported 
no differences in terms of psychotropic medication use by individuals who had transitioned to 
the community. These studies reported inconsistent findings relating to psychotropic medication 
use following deinstitutionalization, which lend support to the need for further research into 
medication patterns and polypharmacy in the context of deinstitutionalization.  
Polypharmacy and Individuals with Intellectual Disabilities 
The definition of polypharmacy varied across studies (e.g., Burd et al., 1997; Esbensen et 
al., 2009; Hurley et al., 2003; McGillivray & McCabe, 2005; Robertson et al., 2000; Stolker et 
al., 2001; Stolker et al., 2002; Stortz et al., 2014;). Some studies included the combination of 
general medications (non-psychotropic) and psychotropic medications within their definition of 
polypharmacy (Ebensen et al., 2009). Other studies limited their definition of polypharmacy to 
multiple psychotropic medications (Burd et al., 1997; Hurley et al., 2003; McGillivray & 
McCabe, 2005). In this study, the definition of polypharmacy is “the combination of two or more 
psychotropic drugs from the same or different medication classes” (Stortz et al., 2014, p. 62). 
This definition was selected because the focus of this study was to examine the predictors of 
polypharmacy as measured by the number of psychotropic medications being used.  
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Many studies examining medication trends among individuals with ID have reported 
considerable reliance on psychotropic medication, high dosages of psychotropic medications, 
and frequent polypharmacy (e.g., Deb, Unwin, & Deb, 2015; Bowring, Totsika, Hastings, 
Toogood, & McMahon, 2017a; Rahim, 2012; Nottestad & Linaker, 2003). Prevalence rates of 
psychotropic medication usage have ranged from 39.2% to as high as 90% across individuals 
with ID (Deb et al., 2015; Lunsky et al., 2017; Tsiouris, Kim, Brown, Pettinger and Cohen, 
2013). The prevalence of polypharmacy among persons with ID was also high, ranging from 7% 
to as high as 59% (Bowring et al., 2017a; Kiernan, Reeves, & Alborz, 1995). Unfortunately, 
individuals with ID may be prescribed these medications to manage CB, rather than to treat 
psychiatric symptoms (Deb et al., 2015; Lunsky et al., 2017, & Nottestad & Linaker, 2003). As a 
result, this vulnerable population is often prescribed psychotropic medications inappropriately 
(Lunsky et al., 2017). These elevated numbers of psychotropic medications (Deb et al., 2015; 
Lunsky et al., 2017) and or elevated dosages of psychotropic medications (Deb et al., 2015; 
Nottestad & Linaker, 2003) highlight the importance of improving documentation to ensure that 
there is a greater understanding of the psychotropic medication usage in this population (Lunsky 
et al., 2017). Secondly, investigating how variables are related to psychotropic medications is 
essential when examining polypharmacy and medication utilization trends. Studies examining 
these relationships included both bivariate and multivariate analyses. In order to determine the 
relevant “predictors” for the models proposed in this thesis, the results of bivariate and 
multivariate studies were considered separately in the following sections. 
Age and psychotropic medication. Most research suggested that age, to a certain extent, 
was associated with psychotropic medication usage (e.g., Bowring et al., 2017a; Deb et al., 2015; 
Sheehan et al., 2015; Tsiouris et al., 2013). Researchers have found that increasing age was 
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associated with psychotropic medication usage in bivariate analyses (Bowring et al., 2017a; Deb 
et al., 2015; O’Dwyer, Peklar, McCallion, McCarron, & Henman, 2016). Other studies examined 
age as a predictor of psychotropic medication usage in multivariate models and found significant 
associations (Bowring et al., 2017a; Sheehan et al., 2015; Tsiouris et al., 2013). Sheehan et al. 
(2015) examined psychotropic medication patterns among individuals with ID (N = 33,016). 
Multivariate Poisson regression analyses were conducted to examine associations between 
medication usage and specific predictor variables. Age was found to be one of the significant 
predictors associated with psychotropic medication use in their model. Similarly, Bowring et al. 
(2017a; N = 267) conducted a generalized linear model and determined that increasing age was 
associated with psychotropic medication usage. Further, Tsiouris et al. (2013) found that as a 
predictor, age was significantly related to psychotropic medication in both a logistic regression 
model for the use versus non-use of psychotropic medication and a Poisson regression for the 
total number of medications. Deb et al. (2015) examined trajectory patterns of antipsychotic 
medication use among individuals with ID who exhibit CB using bivariate comparisons (N = 
100). Antipsychotic medication dosage was positively correlated with age. Lastly, O’Dwyer et 
al. (2016) conducted bivariate analyses and determined that older age was significantly 
associated with excessive polypharmacy defined as 10 or more regular medications and/or 
psychotropic medications.  
In contrast, some studies did not find age to be a significant predictor associated with 
psychotropic medication in multivariate models (O’Dwyer et al., 2017; Spreat, Conroy, & 
Fullerton, 2004). In 2004, Spreat et al. surveyed psychotropic medication patterns among 
individuals with ID in Oklahoma in a stepwise logistic regression model. The authors found that 
age was not a significant predictor associated with psychotropic medication. Further, in a 
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multinomial logistic regression conducted by O’Dwyer et al. (2017), age was not a significant 
predictor associated with psychotropic medications. Given these varying reports, researchers 
should consider age when examining potential predictors of psychotropic medication usage. 
Sex and psychotropic medication. Multiple studies have examined the influence of sex 
on psychotropic medication usage (Bowring et al., 2017a; O’Dwyer, 2017; Spreat et al., 2004; 
Tsiouris et al., 2013). While Bowring et al. (2017a) indicated that maleness was associated with 
polypharmacy (Bowring et al., 2017a), other researchers found that sex did not influence 
psychotropic medication usage (O’Dwyer, 2017; Spreat et al., 2004; Tsiouris et al., 2013). 
Bowring et al. (2017a) determined that maleness was independently associated with an increase 
in psychotropic medication in a generalized linear model. In contrast, using various multivariate 
analyses, O’Dwyer (2017; p = .61) and Tsiouris et al., (2013; p = .07), determined that sex was 
not a significant predictor associated with either psychotropic medication usage or the number of 
psychotropic medications, respectively. Lastly, Spreat et al. (2004) stated that sex was not a 
significant predictor associated with psychotropic medication usage in their stepwise logistic 
regression model. As such, most studies suggested that sex was not associated with an increase 
in psychotropic medication usage. Nonetheless, considering sex is relevant in this thesis as it has 
been included as a potential predictor in many studies, with some variation in results (Bowring et 
al., 2017a; O’Dwyer, 2017; Spreat et al., 2004; Tsiouris et al., 2013). 
Adaptive functioning and psychotropic medication. There have been mixed reports 
exploring the influence of adaptive functioning on polypharmacy (Bamburg, Matson, & Gouvier, 
n.d.; Bowring et al., 2017a; O’Dwyer et al., 2017; Tsiouris et al., 2013). Bamburg et al. (n.d.) 
examined adaptive skills for individuals with ID receiving psychotropic medications. These 
authors determined that individuals who received antipsychotic or mood stabilizer medications 
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had reduced adaptive social scores compared to individuals receiving only anti-seizure 
medication. This suggests that psychotropic medications could be linked to lower adaptive 
functioning scores. Similarly, O’Dwyer et al. (2016) conducted bivariate analyses and 
determined that level of ID was significantly associated with polypharmacy status. Further, 
O’Dwyer et al. (2017) found that level of ID was a significant predictor associated with receiving 
one psychotropic medication in a multinomial logistic regression. However, these results were 
not consistently found in other studies.  
Researchers have found that the level of functioning was not associated with psychotropic 
medication usage (Bowring et al., 2017a; Tsiouris et al., 2013). Bowring et al. (2017a) 
determined that severe-profound ID diagnoses were not significantly associated with 
psychotropic medication usage when all relevant and significant variables were entered in the 
generalized linear model. Similarly, Tsiouris and colleagues (2013) conducted a hurdle analysis 
and determined that the degree of ID did not influence the usage or number of psychotropic 
medications. Lastly, in a multinomial model conducted by O’Dwyer et al. (2017), level of ID 
was not a significant predictor associated with psychotropic polypharmacy. Nonetheless, the 
emphasis that most studies placed on including adaptive functioning or degree of ID variables as 
potential predictors highlighted the importance of considering adaptive functioning when 
examining psychotropic medication usage.  
Health status and psychotropic medication. Health status should be considered when 
examining psychotropic medications. Individuals with ID may exhibit health concerns, including 
physical disabilities, hearing and vision impairment, communication disorders and psychiatric 
diagnoses (Oullette-Kuntz et al., 2005). Increased health concerns, combined with ID, increase 
the risk of this population facing health disparities when compared to the typical population 
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(Oullette-Kuntz et al. 2005; Phillips, Morrison, & Davis, 2004; Sullivan et al., 2018). Persons 
with ID have a lower age at mortality than typical individuals, which highlights the health 
disparity experienced amongst individuals with ID (Heslop, Lauer, & Hoghton, 2015; Lauer & 
McCallion, 2015). Stortz et al. (2014) identified polypharmacy to be an important component to 
examine for evaluating health services for persons with ID, as consuming multiple psychotropic 
medications may be dangerous and often requires additional clinical resources (Sullivan et al., 
2011). These concerns have emerged because persons with intellectual disabilities exposed to 
polypharmacy are more likely to experience side effects than patients in the general population 
and may lack the ability to report or understand these side effects (Lunsky & Modi, 2017). 
Additionally, O’Dwyer et al. (2016) conducted bivariate analyses, which demonstrated that 
various chronic diseases (e.g., neurological, gastrointestinal, joint disease, endocrine disease, 
hypertension, reported pain, etc.) were significantly associated with polypharmacy status. 
Neurological conditions, gastrointestinal disease, endocrine disease, and hypertension were also 
significant predictors associated with polypharmacy in a multinomial logistic regression. As 
such, researchers should consider health status when examining potential predictors of 
polypharmacy.  
Psychiatric diagnoses and psychotropic medication. Psychiatric diagnosis is a critical 
variable to consider when investigating predictors of psychotropic medication usage. Research 
has found that individuals with ID are likely to be prescribed psychotropic medication to treat 
CB in the absence of a corresponding psychiatric diagnosis (Perry et al., 2018). Psychiatric 
conditions are common in this population, with the prevalence of psychiatric illness ranging from 
10 to 39% (Deb, Thomas, & Bright, 2001; Costello & Bouras, 2006). These additional mental 
health challenges, combined with impairments in adaptive skills and intellectual functioning, 
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result in this population facing a higher risk of developing health problems when compared to 
the general population (Oulette-Kuntz et al., 2005; Deb et al., 2001; Sullivan et al., 2018).  
There were mixed reports regarding whether mental health symptoms or diagnoses 
predict or were associated with polypharmacy. Some studies reported a significant association 
between polypharmacy and mental health (Bowring et al., 2017a; Tsiouris et al., 2013), while 
others do not (Deb et al., 2015; Perry et al., 2018). In 2013, Tsiouris and colleagues examined 
the stated reasons for psychotropic prescriptions and determined that 49%, 13%, and 38% of the 
medications were prescribed for psychiatric symptoms, managing CB, and both psychiatric 
symptoms and CB respectively. Further, polypharmacy was highest among individuals with ID 
who had bipolar disorder, psychoses (a core feature of the schizophrenia disorder spectrum; 
Arciniegas, 2015), depression, autism spectrum disorder (ASD), personality disorder and/or 
obsessive-compulsive disorder. Many of these disorders, including bipolar, psychosis, 
depression, and obsessive-compulsive disorder were also significant predictors of the total 
number of psychotropic medications in a Poisson regression. The authors concluded that 
practitioners had treated psychiatric diagnoses among individuals with ID in a manner that 
mirrors treatment for the general public. This article provided support in improvements towards 
evidence-based treatments in psychiatry among individuals with ID. This finding aligned with 
Bowring et al. (2017a)’s study in the UK, which found a statistically significant association 
between the presence of a psychiatric illness and psychotropic medication in a generalized linear 
model. Similarly, Sheehan and colleagues (2015) identified a significant relationship between 
severe mental illness and new antipsychotic prescriptions in a multivariable mixed Poisson 
regression. Conversely, other studies indicated a non-significant relation between polypharmacy 
and mental health diagnoses (Lunsky et al., 2017; Perry et al., 2018).  
PSYCHOTROPIC MEDICATION PATTERNS  19 
Individuals with ID may be prescribed psychotropic medication despite not having any 
psychiatric diagnoses (Lunsky et al., 2017; Perry et al., 2018). Perry et al. (2018) examined CB 
and psychotropic medication in individuals with ID in the UK. Statistically significant Chi-
square associations between recorded psychiatric diagnoses or psychotropic medication were not 
found, which suggested that individuals with ID were prescribed off-label psychotropic 
medications to manage CB. Psychotropic medication trends in Ontario also indicated an over 
usage of psychotropic medication for individuals with ID (Lunsky et al., 2017). Lunsky and 
colleagues (2017) examined antipsychotic medication patterns in individuals with ID across 
Ontario. Overall, 39% of adults with ID were prescribed antipsychotics, and approximately one-
third of these individuals did not have a documented psychiatric diagnosis. The lack of 
associations between psychotropic medications and psychiatric illness may have occurred due to 
these medications being used to treat CB rather than mental health.  
Challenging behaviour and psychotropic medication. Individuals with ID are more 
likely to develop CB, such as aggression, property destruction, self-injurious behaviour, and pica 
when compared to the general population (Emerson et al., 2000; Matson & Neal, 2009). 
Approximately 18% of individuals with ID exhibit significantly dangerous behaviour (Bowring 
et al., 2017b). Bowring et al. (2017b) determined that 18.1% of individuals with ID engaged in 
overall CB, while 7.5%, 8.3% and 10.9% engaged in self-injurious, aggressive-destructive, and 
stereotyped behaviour, respectively. The high rate of occurrence of CB also poses a problem for 
mental health service staff and hospital staff (Matson & Neal, 2009). As a result, mental health 
clinics and institutions often target CB for treatment.  
Multiple studies reported that CB was associated with psychotropic medication use (e.g., 
Deb et al., 2015; Lunsky et al., 2017; Nottestad & Linaker 2003). In 2003, Nottestad and Linaker 
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(2003) investigated psychotropic medication use before and after relocation using a stepwise 
linear regression. The authors determined CB to be the main predictor for psychotropic dosage 
before and after deinstitutionalization, which may emphasize how individuals with ID were 
prescribed medications to manage behaviour rather than for treating psychiatric symptoms. 
Similarly, Deb et al. (2015) examined trajectory patterns of antipsychotic medication use among 
individuals with ID who exhibit CB. Participants were studied across two points in time in clinic-
based community settings across a 6-month period (N = 100). The authors determined that a high 
percentage of participants were prescribed psychotropic medications at baseline and follow-up, 
with 89% and 90% respectively. Doses of antipsychotic medication were positively correlated 
with property destruction, SIB, and severe aggression. Overall, these studies demonstrated the 
relationship between psychotropic medication and CB that continues to persist among 
individuals with ID.  
Psychotropic Medication Across Settings 
There have been multiple studies that have examined psychotropic medication patterns 
among individuals who experienced deinstitutionalization (e.g., Kelly & Su, 2015; McGillivray 
& McCabe, 2005; Nottestad & Linaker, 2003; Rahim, 2012; Spreat et al., 2004). In addition to 
understanding variables associated with psychotropic medication usage over time, investigating 
the changes across settings (i.e., facility to community living) is critical for evaluating the extent 
to which the presence of certain variables may increase or decrease the likelihood of 
polypharmacy as individuals transition from institutions to community living. 
Facilities. The number of psychotropic medications prescribed among individuals with 
ID living in institutions has varied across studies (Kelly & Su, 2015; Nottestad & Linaker, 2003; 
Rahim, 2012). In 2015, Kelly and Sue evaluated medication patterns among individuals who 
PSYCHOTROPIC MEDICATION PATTERNS  21 
transitioned from Georgia, USA institutions. The authors determined the mean psychotropic and 
anticonvulsant usage among individuals to be 68% when persons were living in the facilities. 
This value aligned with other deinstitutionalization studies, such as Nottestad and Linaker’s 
(2003) study, in which 50% of the residents used psychotropic and anticonvulsant medications. 
In contrast, when Rahim (2012) examined psychotropic medication patterns among individuals 
deinstitutionalized in Ontario (same sample as the current study), she indicated that 74.2% of 
participants were prescribed psychotropic medication in the institutions. These higher 
percentages of psychotropic medication usage may have emerged as this study evaluated the 
final group of individuals to experience deinstitutionalization in Ontario. It is possible that these 
individuals represented a subset of individuals who were harder to serve, in that they experienced 
more psychiatric symptoms and/or engaged in more severe CB. This could account for the higher 
psychiatric medication usage among individuals in this sample.  
Transitioning to the community. Many studies suggested an increase in the prevalence 
of psychotropic medication usage among individuals who transitioned to the community from 
institutional settings (Kelly & Su, 2015; Nottestad & Linaker, 2003; Rahim, 2012). In 2015, 
Kelly and Su evaluated psychotropic and anticonvulsant medication patterns among individuals 
with ID who transitioned from Georgia, USA institutions to community living (N = 325). 
Psychotropic medications usage among individuals with ID who had never lived in an institution 
was also collected to serve as a comparison group (N = 12,722). The authors determined that the 
increases observed among individuals who had recently transitioned were significantly higher 
when compared to when these individuals were living in institutions (M = 0.68 and M = 1.84, 
respectively). The recently transitioned group also demonstrated significantly higher 
psychotropic medication values when compared to the comparison group (M = 1.01 and M = 
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1.98, respectively). These findings emphasized the importance of evaluating persons who 
experienced deinstitutionalization specifically, as their psychotropic medication patterns may 
differ from individuals who have always lived in community settings. Similarly, Rahim (2012) 
indicated that psychotropic medication usage increased significantly when individuals 
transitioned to the community (M = 74.2% and M = 83.3%, respectively). Lastly, Spreat et al. 
(2004) examined individuals with ID who either stayed or left the institutions. There was an 
increase in the use of antidepressant and anxiolytics medications (6.6% and 3.0% respectively; p 
< .05) but no significant difference in antipsychotic medications among individuals who 
relocated to community settings.  
Some studies found that psychotropic medications were higher for those living in 
institutions. McGillivray and McCabe (2005) examined the patterns of psychotropic medication 
for managing CB and places of residence among individuals with ID between 1993 and 2000 (N 
= 873). Bivariate analyses were conducted to compare medication usage across two settings. In 
1993, individuals living in the institutions received a larger number of medications compared to 
those in the community. Similarly, in 2000, polypharmacy was greater among participants living 
in institutions, however, the proportion of psychotropic medications prescribed relative to the 
population was not different across facility and community settings  
Other studies have found a lack of consistency in psychotropic medication usage across 
institutions and community settings (McGillivray & McCabe, 2005; Nottestad & Linaker, 2003). 
In 2003, Nottestad and Linaker examined psychotropic medication patterns among individuals 
who were deinstitutionalized in Norway (N = 109). Nottestad and Linaker (2003) found no 
significant changes related to psychotropic medication patterns when individuals transitioned to 
the community (M = 50% in institutions, M = 54% in the community). Further, the authors 
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conducted a stepwise linear regression to examine variables that predicted medication usage. 
Nottestad and Linaker (2003) determined that there were no significant changes in neuroleptic 
usage across the settings. Similarly, McGillivray and McCabe (2005) determined that the 
proportion of participants prescribed medication was not significantly different when comparing 
persons living in institutions or facilities. These results emphasized that transitioning to the 
community does not necessarily result in a change in psychotropic medication prescriptions 
among individuals with ID. Overall, these findings emphasized that additional examination of 
polypharmacy across settings may reveal areas for health care practitioners to target in order to 
improve health care service provided to individuals with ID. 
Longitudinal Research 
 Given the lack of consistent findings across studies that examine polypharmacy over time 
among individuals with ID who experienced deinstitutionalization (Kelly & Su, 2015; Nottestad 
& Linaker, 2003; Rahim, 2012), additional longitudinal studies are necessary to determine the 
predictors of changes and patterns of psychotropic medication use over time.  
Multilevel models. Within the past decade, a common method for analyzing longitudinal 
data has been the multilevel analysis (Curran, Obeidat, & Losardo, 2010). Although researchers 
previously examined psychotropic medication patterns among individuals with ID who relocated 
to community settings, most studies only examined changes across two points in time (Nottestad 
& Linaker, 2003; McGillivray & McCabe, 2005; Willet & Sayer, 1994). By capturing 
“snapshots” over more points in time, additional information can be provided to inform the 
extent to which individual characteristics influence an individual’s change over time (Willet & 
Slayer, 1994).  
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In a multilevel model, an individual growth model is used to demonstrate the change 
single individuals experience over time (Willet & Sayer, 1994). This level of the model is 
referred to as within-person variation or the “level 1 model”, or fixed effects (Willet & Sayer, 
1994, p. 363). The second level of a multilevel analysis refers to the relationship between the 
individual growth trajectories and the predictors of change, thereby representing the between-
person variation (Willet & Sayer, 1994). By including an analysis of both fixed (within-person) 
and random (between persons) effects, multilevel models examine “between-person differences 
in within-person change” (Curran et al., 2010, p. 121). Therefore, a multilevel model would 
account for the extent to which individual characteristics influence the overall model, whereas a 
generalized estimating equation would not. Further, this type of strategy may be more effective 
than other generalized estimating equation strategies, such as multivariate analysis of variance 
(MANOVA), as individuals missing data at certain points in time could still be counted in the 
overall model (Fitzmaurice, Laird, & Ware, 2004).  
Research Gaps 
There are various limitations demonstrated in previous research that examined 
polypharmacy trends among individuals with ID. Storz et al. (2014) emphasized that 
improvements could be made when analyzing polypharmacy trends among individuals with ID 
by incorporating multivariate analyses. Further, Sheehan et al. (2015) indicated that few studies 
had examined psychotropic medication patterns among adults with intellectual and or 
developmental disabilities (IDD) with a longitudinal design (Deb et al., 2015; Nottestad & 
Linaker, 2003; Rahim, 2012). Most deinstitutionalization studies only evaluated psychotropic 
patterns across two points in time (Nottestad & Linaker, 2003; Rahim, 2012). Lastly, no studies 
to date were found that evaluated psychotropic medications among individuals who experienced 
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deinstitutionalization using a multilevel model analysis, which would account for individual 
differences when examining polypharmacy trends across settings and over time. By examining 
this population using a multilevel longitudinal model across three points in time, more 
information may be obtained that could potentially inform the regulation of polypharmacy and 
long-term psychotropic medication usage among individuals with ID.  
Significance: Informing Regulation 
 Sullivan et al. (2018) created the Primary Care of Adults with Intellectual and 
Developmental Disabilities: 2018 Canadian Consensus Guidelines. This study updated the 2011 
Canadian guidelines for primary care of individuals with ID and provided recommendations for 
improving the care that individuals with ID received from family physicians and health 
professionals. The guidelines emphasized that a person-centered approach should be 
implemented, which considers the importance of effective communication and the individual’s 
capacity for making decisions. Emphasis was also placed on team building and ensuring that 
health care teams are developed in a manner that provides interdisciplinary support. Health care 
status was discussed thoroughly in these updated guidelines, with a focus on consistent health 
assessments and assessing adaptive functioning. Sullivan et al. (2018) also indicated that 
assessment of mental health care should be implemented consistently. This guideline included 
assessing mental health symptoms and CB. Screening should be conducted by assessing changes 
from baseline in behaviour and mental state. A final set of guidelines thoroughly addressed 
polypharmacy.  
These guidelines emphasized the importance of understanding polypharmacy and the use of 
psychotropic medications to manage mental health symptoms, diagnoses and CB. In particular, 
Sullivan et al. (2018) indicated that polypharmacy and long-term use of psychotropic 
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medications are highly prevalent among individuals with ID. Further, the authors highlighted that 
adverse reactions to psychotropic medications might impact QoL. Their recommendations 
included reviewing current medications every three months, establishing a baseline for 
medications, and informing the individual with ID and his or her caregivers of all the relevant 
components of psychotropic medication (i.e., appropriate use, interactions with other 
medications, etc.).  
Other Canadian researchers highlighted the importance of improving the current 
inappropriate percentages of antipsychotic prescriptions (Lunsky et al., 2017). The authors 
suggested that the use of chart audits and feedback mechanisms might improve the field’s 
understanding of psychotropic medication usage and the extent to which relevant guidelines are 
followed. In the current study, by examining both the changes in psychotropic medication usage 
as well as potential predictors of polypharmacy, a greater awareness of the patterns may emerge. 
In turn, the findings could be used as suggestive evidence to inform new policies or to revise 
guidelines for prescribing psychotropic medication for individuals with ID in Ontario.  
Summary 
 Individuals with ID who experienced deinstitutionalization are more likely to be exposed 
to polypharmacy than the general population (McGillivray & McCabe, 2005; Stortz et al., 2014). 
To begin to address the current practice of overprescribing of psychotropic medications, 
thorough examinations of the variables associated with polypharmacy should be conducted 
(Stortz et al., 2014). The purpose of this study is to contribute to the body of research examining 
psychotropic medication usage among individuals with ID who experienced 
deinstitutionalization across three points in time: before leaving the facility, after moving to the 
community, and at a subsequent community follow-up visit. By examining data that spans across 
PSYCHOTROPIC MEDICATION PATTERNS  27 
more than two points in time, a more thorough understanding of within-person changes may be 
considered (Willet & Sayer, 1994). Further, the use of a multilevel model ensures that between-
person differences are understood with reference to the within-person changes over time (Curran 
et al., 2010; Willet & Sayer, 1994). By understanding how an individual’s characteristics 
contribute to the model, scientists and practitioners may more thoroughly understand predictors 
that influence psychotropic medications across the entire sample while still accounting for 
individual change.  
Research Questions 
1.  What is the mean number of psychotropic medication usage across each point in time in 
this sample? 
2. What are the relationships between psychotropic medication, age, sex, cognitive 
performance, adaptive behaviour, medical diagnoses, serious health conditions, pain, 
psychiatric diagnoses, depression, and CB?  
a. Age was hypothesized to be positively correlated with an increase in psychotropic 
medication usage (Bowring et al., 2017a; Deb et al., 2015; Sheehan et al., 2015; 
O’Dwyer et al., 2017).  
b. Sex was not hypothesized to be correlated with psychotropic medication usage 
(O’Dwyer, 2017; Spreat et al., 2004; Tsiouris et al., 2013). 
c. Health status was hypothesized to be positively correlated with psychotropic 
medication usage (Ouellette-Kuntz et al., 2005; Sullivan et al., 2018). 
d. Adaptive functioning was not hypothesized to be correlated with psychotropic 
medications (Bowring et al., 2017a; Tsiouris et al., 2013).  
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e. Increased mental health symptoms and or psychiatric diagnoses were 
hypothesized to be positively correlated with psychotropic medications (Bowring 
et al., 2017a; Sheehan et al., 2015; Tsiouris et al., 2013). 
f. CB was hypothesized to be positively correlated with psychotropic medications 
(Deb et al., 2015; Lunsky et al., 2017; Nottestad & Linaker, 2003). 
3. Do age, sex, cognitive performance, adaptive behaviour, medical diagnoses, serious 
health conditions, psychiatric diagnoses, depression, pain, and CB predict the total 
number of psychotropic medications? What are the relative influences of each variable? 
Do these influences change over time and across settings? 
a. Age was hypothesized to predict an increase in psychotropic medication usage 
(Bowring et al., 2017a; Deb et al., 2015; O’Dwyer et al., 2017; Sheehan et al., 
2015).  
b. Sex was not hypothesized to predict psychotropic medication usage (O’Dwyer, 
2017; Spreat et al., 2004; Tsiouris et al., 2013). 
c. Individuals with additional health challenges were hypothesized to be taking a 
greater number of psychotropic medications than those with fewer health-related 
challenges (Ouellette-Kuntz et al., 2005; Sullivan et al., 2018).  
d. Adaptive functioning was not hypothesized to predict psychotropic medications 
(Bowring et al., 2017a; Tsiouris et al., 2013).  
e. Individuals with increased levels of mental health symptoms or numbers of 
diagnoses were hypothesized to receive a higher number of psychotropic 
medications than those with fewer mental health symptoms or diagnoses 
(Bowring et al., 2017a; Sheehan et al., 2015; Tsiouris et al., 2013).  
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f. Individuals displaying increased levels of CB were hypothesized to be taking a 
greater number of psychotropic medications than individuals with no CB (Deb et 
al., 2015; Lunsky et al., 2017; Nottestad & Linaker 2003).  
Methods 
Participants 
 The data for this study were gathered as part of the QL component of the FI study, which 
included data collected from 2005-2008 within the facilities, and follow up data collected 
between 2009 and 2012. The sample included 120 participants (67 males, 52 females, one 
missing) who had relocated from the remaining three Ontario institutions (i.e., Rideau Regional 
Centre, Southwestern Regional Centre, and Huronia Regional Centre). Participants were an 
average age of 55.05 when the assessment was completed for C1 (SD = 0.73), ranging from 
33.43 to 77.10 years of age. Participants demonstrated various degrees of cognitive and adaptive 
abilities. 
Recruitment 
The FI study consisted of relocating 941 former residents with ID into community 
settings. Data collection for the original study started in March 2010, almost a year after the 
closure date of March 31, 2009. Initial recruitment started in August 2009. This initial 
recruitment consisted of the MCSS sending consent to contact forms to the agencies currently 
support former residents. Methods for contacting included email and telephone contact via 
Executive Directors of community services, circulation of flyers through community 
organizations, and a one-page flyer listed in the Networks of Specialized Care. This recruitment 
process resulted in a total of 120 individuals participating in the study, thereby representing 
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12.75% of the individuals who experienced relocation during the Facilities Initiative study. Data 
collection ended in December of 2011. 
Consent for participation. After consent to contact forms were completed and received 
by the researchers, a consent form was sent to the individual with ID or his/her family member. 
Consent to collect new information from individuals and their direct care staff, to access 
information from their facility files and for subsequent analyses related to the original research 
questions was obtained from participants (or their substitute decision-makers) prior to the first 
and second community visits. In the case of proxy consent, assent was sought from individuals at 
the time of community visits. Only one participant declined to participate in part of the data 
collection requiring his/her direct involvement but gave consent for staff to provide information 
to research assistants directly. Research ethics board (REB) clearance was previously obtained, 
which included consent for the usage of data for future studies. 
Sampling. A critical component of research interpretation is evaluating if individuals 
who participated in the study are similar or different than those who did not participate. An 
analysis was completed to examine the similarities and differences between the 894 individuals 
who did not participate in this study and the 120 participants who lived in the facilities with them 
in 2005. Chi-square analyses were conducted using Statistical Package for the Social Sciences 
(SPSS v. 26) to compare the location (facility), age (in 2005), sex, primary method of 
communication, severity of communication impairments (expressive and receptive), CPS, 
adaptive functioning (ADL Hierarchy Scale), pain, health instability (Chess), aggression (ABS), 
and depression (DRS). Independent t-tests were used to compare the average age, adaptive 
functioning score (IADL-Perf), and the average number of health conditions. Results from the 
comparison are listed in Table 1.  
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Table 1 Baseline (2005) Sample Characteristics 
Baseline (2005) Sample Characteristics 
 
 Individuals 
with one 
community 
assessment 
Individuals 
without any 
community 
assessments 
Test statistic 
  N=120 N=894 
 
   % %   
Institution      
Huronia Regional Centre 
(L3V) 
 
33.6 33.1 
X2 = .792  
(df = 2) 
Rideau Regional Centre 
(K7A) 
 
27.7 42.4 p = .675 
Southwest Regional Centre 
(N0P) 
 
38.7 24.5   
Average Age (SD)*  49.82 (7.90) 51.79 (9.59) t = 2.47 
  
  (df = 167.63) 
     p = .014 
Age Categories* 
 
  
X2 = 6.109  
(df = 1) 
Under 50 years  60.00 47.99 p = .013 
50+ years  40.00 52.01  
Male 
 
55.5 63 
X2 = 2.558 
(df =1) 
     p = .110 
Primary Method of 
Communication 
 
   
Verbal 
 
25.8 30.5 
X2 =1.080  
(df = 1) 
Non-Verbal  74.2 69.5 p = .299 
Severely Impaired 
Communication  
 
    
     
Expressive     
Understood, usually 
understood, often understood 
(0-2) 
 
24.2 24.4 
X2 = .0034  
(df = 1) 
Sometimes/rarely/never 
understood (3-4) 
 
75.8 75.6 p = .958 
     
Receptive     
Understands, usually 
understands, often 
understands (0-2) 
 
37.5 34.3 
X2 = .466  
(df = 1) 
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Sometimes/rarely/never 
understands (3-4) 
 
62.5 65.7 p = .495 
       
Cognitive Performance Scale 
(CPS) 
 
  
X2 = 11.935  
(df = 6) 
Intact (0)  0 0.2 p = .063 
Borderline intact (1)  3.3 2.9  
Mild cognitive impairment (2)  3.3 3.1  
Moderate cognitive 
impairment (3) 
 
14.2 12  
Moderate to severe cognitive 
impairment (4) 
 
17.5 8.5  
Severe cognitive impairment 
(5) 
 
45.8 51.7  
Very severe cognitive 
impairment (6) 
 
15.8 21.4   
ADL Hierarchy Scale (ADL-
H) 
 
  
X2 = 8.399  
(df = 6) 
Independent (0)  2.5 4.1 p = .210 
Supervision required (1)  12.5 8.5  
Limited assistance required 
(2) 
 
8.3 5.3  
Extensive assistance required, 
level 1 (3) 
 
41.7 41.8  
Extensive assistance required, 
level 2 (4) 
 
7.5 4.8  
Dependent on others (5)  15.8 17.7  
Totally dependent on others 
(6) 
 
11.7 17.8   
Average IADL Performance 
Scale (SD) 
 
47.38 (1.70) 47.25 (2.50) 
t = -.274 
    (df = 191) 
     p = .785 
Pain Scale 
 
  
X2 = 3.347  
(df = 3) 
No pain (0)  80 76.6 p = .341 
Less than daily pain (1)  16.7 15.8  
Daily pain but not severe (2)  2.5 6.8  
Severe daily pain (3)  0.8 0.8  
Health Instability (Chess) 
 
  
X2 = 6.546  
(df = 4) 
Not at all unstable (0)  87.4 82.5 p = .162 
(1)  10.9 13  
Unstable (2)  0 3.4  
(3)  1.7 0.7  
Highly unstable (4)  0 0.5   
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Aggressive Behaviour Scale 
 
  
X2 = 4.758  
(df = 2) 
None (0)  32.8 40.5 p = .093 
Mild to moderate (1-5)  61.3 50.9  
Severe (6+)  5.9 8.6   
Depression Rating Scale  
 
  
X2 = 0.415 
(df = 1) 
None (0)  85.8 87.9 p = .519 
Possible depression (3+)  14.2 12.1   
Average Number of Health 
Conditions (SD) 
 
3.89 (4.690) 3.85 (4.729) 
t = -.093  
(df = 1012) 
  
 
    p = .926 
Note. Table was based on Condillac et al. (2012, p. 20-21); *p < .05. 
The results indicated that with the exception of age (p < .05; Table 1), there were no 
significant differences between the 120 individuals who participated in the study and the 894 
who had not participated across several key characteristics (p > .05; Table 1). The average age of 
others in the facility in 2005 was higher (M = 51.79, M = 49.82; respectively) than the average 
age of individuals in our sample at that time (p = .014). When the populations were divided into 
above and below 50 years of age, there were significantly more individuals in this sample who 
were under the age of 50 (60% and 48% for N = 120 and N = 894 respectively, p = .013). The 
current sample was considered representative of the population of the facilities in 2005.  
Measures 
 InterRAI-ID. The interRAI-ID (Martin, Hirdes, Fries, & Smith, 2007) is a 
comprehensive measure evaluating key domains of an individual with ID’s life. The interRAI-ID 
includes 391 items that examine 20 domains of life, including: personal information, health 
service history, cognition, communication, hearing and vision, physical functioning and self-
care, physical health, medications, skin conditions, oral and nutrition status, psychiatric 
disorders, mental state indicators, life events, behaviour, psychosocial well-being and social 
supports, education, vocation, recreation, prevention and intervention, and home environment 
PSYCHOTROPIC MEDICATION PATTERNS  34 
(Martin et al., 2007). The measures embedded in the interRAI-ID instruments are valid and 
internally consistent among individuals with ID (Martin et al., 2007). The interRAI-ID consists 
of ten subscales described below. However, there are limitations to this measure. In particular, 
the interRAI-ID only requires medications to be recorded if they have been administered within 
the last three days. The interRAI-ID consists of ten subscales described below. 
 Activities of Daily Living Hierarchy Scale. This scale evaluates an individual’s ability 
to complete everyday activities (Condillac et al., 2012). Items on this scale include personal 
hygiene, mobility, toilet use, and eating. Scores can range from 0 (independent) to 6 (totally 
dependent). This scale is inverted as lower scores represent increased adaptive functioning.  
 Independent Activities of Daily Performance Scale. The Independent Activities of 
Daily Performance Scale (IADL-Perf) evaluates an individual’s ability to complete IADLs, such 
as meal preparation, phone use, ordinary housework, shopping, managing finances, 
transportation, and managing medications and work (Condillac et al., 2012). Scores may range 
from 0 to 48, with lower levels representing reduced assistance required (Condillac et al., 2012).  
 Cognitive Performance Scale. The Cognitive Performance Scale (CPS) evaluates four 
items (short-term memory, decision-making, expression, and self-performance in eating) to 
determine a predictive algorithm for cognitive status (Martin et al., 2007). The CPS may also be 
used over time to evaluate if cognitive status declines as a function of age. This scale is a 7-point 
Likert scale. Scores vary from intact (0), borderline intact (1), mildly impaired (2), moderately 
impaired (3), moderately to severely impaired (4), severely impaired (5) to very severely 
impaired (6). This scale is inverted in that, lower scores indicate higher cognitive performance. 
The internal consistency of this scale was not previously calculated as the CPS is a predictive 
algorithm (Martin et al., 2007).  
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 Depression Rating Scale. The Depression Rating Scale (DRS) consists of the summation 
of seven items that may indicate possible depression over the last three days (Martin et al., 
2007). The items are possible indicators of depression, which include negative statements, 
persistent anger, expressions of unrealistic fears, repetitive health complaints, repetitive anxious 
complaints, worried facial expression, and crying or tearfulness (Martin et al., 2007). The scale 
ranges from 0 to 14, with a score of 3 indicating possible depression. The DRS demonstrates 
good internal consistency for adults with ID, with Cronbach’s alpha scores of 0.79 and 0.78 
across psychiatric and complex continuing care settings, respectively (Martin et al., 2007).  
 Aggressive Behaviour Scale. This scale consists of the sum of four items: verbal abuse, 
physical abuse, resistance to care, and socially inappropriate disruptive behaviour to determine 
the level of aggression exhibited by an individual across three days (Martin, Hirdes, Fries, & 
Smith, 2007). Scores may range from 0 to 12, in which a 12 reflects the highest possible score 
for aggression. This scale demonstrates a high internal consistency in complex continuing care 
(Cronbach’s alpha= .93) but a weaker internal consistency among adults with ID living in 
inpatient psychiatry settings (Cronbach’s alpha= .59; Martin et al., 2007). 
 Pain Scale. The pain scale evaluates a person’s level of pain in his or her everyday life 
(Condillac et al., 2012). The items evaluated include the intensity and frequency of pain. Scores 
may range from 0 to 4, with 0 representing no pain and 4 indicating severe daily pain (Condillac 
et al., 2012).  
 Negative Symptoms Scale. The Negative Symptoms Scale (NSS) examines to the extent 
to which an individual exhibits the following negative symptoms: expressions demonstrating a 
lack of pleasure, withdrawal, lack of motivating and decreased social interaction (Condillac et 
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al., 2012). This scale consists of scores ranging from o to 12, with higher scores reflecting more 
severe negative symptoms (Condillac et al., 2012).  
 Changes in Health, End-stage Disease, Signs, and Symptoms. This score was created 
by adding items in a variety of health-related measures (i.e., cognitive decline in last 90 days, 
adaptive daily living in last 90 days, shortness of breath, dehydration, edema, vomiting, weight 
loss, decrease in the amount of food/fluid, and instability of conditions). Item scoring ranges 
from 0 to 4, in which 0 represents not unstable, and 4 represents highly unstable. Further, Hirdes, 
Dinnus, and Teare (2003) determined that CHESS is a strong predictor of mortality (p < .001). 
 Behaviour Problems Inventory (BPI; Rojahn, 1984). The BPI includes 52-items with 
3 subscales examining self-injurious behaviours (SIB), stereotypical behaviours, and 
aggressive/destructive behaviours. In 1989, Rojahn, Polster, Mulick, and Wisniewski examined 
the scale by testing for interrater and retest reliability. Overall, the authors found that most items 
had acceptability reliability scores, particularly the aggression subscale items.  
 Total number of psychiatric diagnoses. A total number of psychiatric diagnoses was 
calculated by summing the presence or absence of four types of psychiatric diagnoses: cognitive 
disorders, psychotic disorders, mood disorders, and anxiety disorders.  
 Total number of medical diagnoses. A total number of medical diagnoses was created by 
adding the absence or presence of the following medical disorder: asthma, cerebral palsy, diabetes 
mellitus, epilepsy or seizure disorder, hypothyroidism, and traumatic brain injury.  
 Total behaviour composite. A CB variable was created by summing relevant measures 
on the Behavioural Symptoms section of the interRAI-ID. Relevant measures were determined 
based on the BPI (Rojahn et al., 1989). 
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Procedure 
 Data collection. After completing the consent and recruitment processes, research 
assistants (RAs) booked a visit with the individual and his/her support worker. Experimenters 
sent a pre-visit package to the support staff, which included various measures for the staff 
informant to complete prior to the visit (interRAI ID; SIB-R, Bruininks et al., 1996; the Reiss 
Screen, Reiss, 1988; and the BPI, Rojahn, et al., 1989). In the current study, only measures on 
the interRAI-ID were analyzed. When the research assistant arrived, assent was obtained from 
the individual. In addition, if staff informants had not fully completed the pre-visit package, 
researcher assistants supported informants on the remaining sections. Notably, measures were 
primarily completed by the staff informants. However, if the individual wanted to participate, 
he/she could assist with completing the measures, though this happened infrequently, given the 
limited communication skills of individuals in this sample. Research assistants conducted 
behavioural observations with the participant and support staff. After completing the visit, 
research assistants returned the measures to the lab, entered the results into a database, and then 
double-checked entries for accuracy. Analyses were completed using SPSS (v.19 - v.26). 
Statistical analyses for the current study are described below.  
Data analyses.  
Missing variables. The Little’s Missing Completely at Random (MCAR) test was 
conducted to determine if values from all the relevant variables were missing completely at 
random. MCAR was conducted for any data points that overlapped with 0. The following time 
variables were created for the current study:  
• A time variable with three points in time (time = F1 = 0; C1 = 1; C2 = 2) 
• Facility to community change time variable (time variable 1= F1 = 0, C1 = 1, C2 = 1) 
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• Within community change (time variable 2 = F1 = 0, C1 = 0, C2 = 1). 
As such, the MCAR test was conducted across F1 and C1 for the relevant variables (e.g., 
psychotropic medications, CPS, ABS, DRS, IADL-Perf, age, pain, CHESS, NSS, etc.). The 
results of the Little’s MCAR for F1 were X2 = 10.359 (df = 8, N = 120; p = .241). As a result, the 
null hypothesis that the data was missing completely at random was not rejected. The Little’s 
MCAR for C1 also demonstrated that the missing data in C1 was missing completely at random 
(X 2= 4.170l df = 7, N = 120; p = .760). 
Evaluating variables. The preliminary analysis of the interRAI-ID scales was conducted 
by examining the descriptive statistics for each variable. The distribution of the variables and 
outliers were evaluated using histograms and boxplots, respectively. Skewness and kurtosis 
values were examined. When variables were not normally distributed (e.g., skewness and 
kurtosis values exceeding values of three; Field, 2013), they were transformed as necessary (e.g., 
square root transformations) using the SPSS compute variable function.  
Outliers. Potential outliers were initially examined using boxplots. Certain cases were 
found outside of the whiskers of the boxplot for the following variables: the total number of 
psychotropic medications, the total number of psychiatric diagnoses, the total number of medical 
diagnoses, ABS, Pain, NSS, and CHESS. CPS, adaptive functioning, and the square root 
transformation of DRS did not have any outliers. No cases were excluded from the dataset as the 
cases that were outliers were frequently only one value past the whiskers of the boxplot. Outliers 
were also examined by plotting the residuals of the multilevel model  
Assumptions. Given that multilevel linear models are considered an extension of linear 
modeling, the typical assumptions of linearity, normality, homogeneity of variance, and 
independence apply (Field, 2013). The linearity assumption was tested by comparing a 
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randomized dummy variable to the number of psychotropic medications. A linear relationship 
between the dummy variable and the IVs was not found (Adjusted R2 = .001, p = .420). 
Normality of the model was examined for each model by plotting the residuals. 
Therefore, these graphs were completed for the null, null growth, base model, and the final 
model. All the models, excluding the null and null growth model, appeared to have normally 
distributed residuals (Figures 1, 2, 3, and 4). Both the null and null growth models appeared to be 
positively skewed. However, an additional factor to consider is the central limit theorem, which 
indicates that as sample size increases, distributions become increasingly normally distributed 
(Field, 2013). Given that this study has 120 participants with two data points and that 86 of these 
participants have three data points, it can be concluded that the normality assumption was met.  
 
Figure 1. Histogram and boxplot of the residuals of the null multilevel model. 
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Figure 2. Histogram and boxplot of the residuals of the null growth multilevel model. 
 
 
Figure 3. Histogram and boxplot of the residuals of the base multilevel model with covariates 
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Figure 4. Histogram and boxplot of the residuals of the final model. 
The third assumption is homogeneity of variance, which refers to if the spread of 
psychotropic medication was consistent across F1, C1, and C2. Residuals and predictive values 
were standardized. The standardized predictive values were graphed against the standardized 
residual values. The cloud-like formation demonstrates that the dataset met the assumption of 
homogeneity of variance.  
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Figure 5. The standardized predictive values plotted against the standardized residuals values 
from the final model. 
The independence assumption was tested by a regression model that was completed with 
all the IVs (excluding the time variables), and the psychotropic medication as the outcome 
variable. The Durbin-Watson value was 1.245, given that this falls between one and three 
indicate that the model did not violate the independence assumption. Lastly, multicollinearity 
was tested by examining the relationships between all the variables (Table 4), which indicated 
that the variables were not highly correlated.  
Variable creation. To ensure that the most appropriate variables were considered for the 
model, additional variables were calculated based on the measures available in the interRAI-ID. 
A mental health status variable was calculated by summing the total presence or absence of 
cognitive disorders, psychotic disorders, mood disorders, and anxiety disorders. A health status 
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variable was created that summed the presence or absence of asthma, cerebral palsy, epilepsy or 
seizure disorder, hypothyroidism, and traumatic brain injury. Lastly, a CB variable was created 
by summing relevant measures on the Behavioural Symptoms section of the interRAI-ID. 
Relevant measures were determined based on the BPI (Rojahn et al., 1989). This included the 
summation of verbal abuse, socially inappropriate and disruptive behaviour, inappropriate public 
sexual behaviour or disrobing, self-injurious behaviour, destructive behaviour, pica, intimidation 
of others or threatened violence, violence to others, or extreme behaviour disturbance. An 
additional composite CB variable was created for C1 and C2 that included physical abuse as well 
as there was not a physical abuse variable available for F1.  
For all the created variables, bivariate correlations were conducted to compare the total 
number of psychiatric diagnoses and the DRS and NSS scale, the total number of medical 
diagnoses and the pain and CHESS scales, and the total CB composite to the ABS.  
Mean calculations. The mean number of psychotropic medications were calculated for 
all participants across each point in time (F1= facility 1; C2 = community 1, and C3 = 
community 2). A line graph was used to display the mean numbers of psychotropic medications 
across F1, C1, and C2. 
Multilevel model. 
 Null model. The null model was conducted by running a mixed model analysis with total 
psychotropic medications entered as the dependent variable. No fixed or random effects were 
entered. The Toeplitz heterogeneous matrix was selected as the covariance pattern. Maximum 
likelihood (ML) was used as the estimated method. Toeplitz heterogeneous matrix and ML were 
used for all models.  
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 Null growth model. To determine the appropriate null growth model, three time variables 
were created: a time variable with three points in time (time; F1 = 0; C1 = 1; C2 = 2) and two 
dummy time variables to compare facility to community change (FC Change; F1 = 0, C1 = 1; C2 
= 1), and within community change (CC Change; F1 = 0; C1 = 0; C2 = 1). Exploratory analyses 
were conducted to determine the best fit for the null growth model. For instance, certain 
variables were inputted as either random or fixed effects. The most appropriate null growth 
model was selected based on two components: 1) model convergence; and 2) lowest AIC and 
BIC scores. The most appropriate null growth model had the variables FC and CC change 
entered as fixed effects and time inputted as a random effect. 
 Base model with covariates. A second model was created that incorporated the covariates 
age and adaptive functioning (IADL-Perf). These variables were grand mean centered by 
subtracting the mean from each variable. These covariates were selected to control for individual 
characteristics differences and were therefore entered as fixed effects to account for within-
individual variation.  
Base with substantive predictors. Following the creation of the base model with 
covariates, other variables and their interactions with the time variables were entered one at a 
time as fixed effects and examined as separate models. Relevant variables were grand mean 
centered by subtracting the mean value from the variable. Given that this analysis was primarily 
exploratory, predictors were entered in one at a time to limit predictors to an acceptable level for 
the sample size. For instance, the DRS variable and the interactions with FC and CC change 
were entered into the basic model as predictors of fixed effects. Following, DRS was removed 
from the model, and the CPS was entered as a fixed effect and so on. This method was 
completed for the following variables: CPS, DRS, NSS, CHESS, pain, ABS, total psychiatric 
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diagnoses, and total medical diagnoses. This strategy was completed to examine which variables 
best predict the usage of psychotropic medication over time and across settings. Transformed 
variables were entered in as their non-transformed versions to ensure that interpretations of the 
outcomes were clear (e.g., non-transformed DRS was entered rather than the square root 
version).  
If the model did not converge with certain predictors, the predictor was entered 
independently of the FC and CC interactions. This strategy was completed for NSS and the total 
number of diagnoses. For NSS, the model did not converge following this change. Given that 
NSS was similar for each participant (e.g., 86 participants did not experience a change in the 
NSS from F1 to C1), the NSS was entered as a fixed variable. The NSS in the facilities was used 
as the fixed measure for this variable. This measure was entered without the interactions with FC 
and CC change.  
Final model and model evaluation. The final model was selected based on the 
information criterion as well as which variables were significant predictors. Given that the 
primary focus of this examination was exploratory, strategies were used to ensure that predictor 
ratios remained at reasonable levels. First, individual predictors were evaluated separately prior 
to their inclusion in the multilevel model. Predictors that were not interacting with any changes 
in the model were removed from the analysis. Secondly, for all the multilevel models, the 
information criteria, including the Akaike’s Information Criteria (AIC), -2 Log Likelihood, and 
Schwarz’s Bayesian Criterion (BIC) were examined to determine the most models that best fit 
the data. The residuals of each model were also saved and graphed to ensure all models were 
normally distributed. The predicted values of each model were also saved. For the significant 
predictors, the variables were binned as follows: CHESS = not at all unstable and unstable; 
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Pain= no pain and pain; CPS= intact to intact borderline, mild to moderate, and moderate to 
severe; total diagnoses= no diagnosis, 1 diagnosis, or more than 1 diagnosis. Mean plots were 
created to examine the changes in the predictive scores over time and across settings for various 
levels of each predictor. 
Post Hoc Analyses 
 Given the lack of influence of CB on psychotropic medication usage, post hoc analyses 
were conducted to examine potential differences between the CB measure used (ABS) and the 
BPI. A comparison between ABS and BPI was conducted at C1 given that this point in time 
represented the larger community sample size and because the BPI had been conducted at this 
point in time. Pearson correlations were conducted to compare the ABS to the BPI. Secondly, 
interquartile ranges were examined across ABS and BPI to evaluate differences in the spread of 
participants’ scores across each variable.  
Results 
Evaluating Variables 
Descriptive summaries of relevant variables are reported in Table 2. Age, the total 
number of psychotropic medications, total medical diagnoses, total psychiatric diagnoses, CPS, 
and IADL-Perf appeared to be relatively normally distributed, with skewness and kurtosis values 
remaining between -2 and 2. The following variables were transformed using the square root 
function: DRS, NSS, ABS, CHESS, and Pain. After transforming these values, skewness and 
kurtosis values were improved (between -2 and 2 for all variables excluding NSS).  
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Table 2 Descriptive Summary of Variables. 
Descriptive Summary of Variables 
Variables N M SE SD  Min.  Max. Skewness Kurtosis 
Age at C1 119 55.05 0.73 8.00 33.43 77.10 0.53 0.46 
Total number of 
psychotropic medications 
318 2.33 0.11 1.91 0.00 9.00 0.60 -0.19 
Total medical diagnoses 315 0.91 0.05 0.80 0.00 3.00 0.61 -0.08 
Total psychiatric 
diagnoses 
313 0.46 0.04 0.76 0.00 3.00 1.57 1.65 
Total behaviour 
composite 
315 4.84 0.29 5.08 0.00 23.00 1.42 1.83 
IADL Performance 290 31.28 0.64 10.90 0.00 48.00 -0.49 -0.02 
ADL Hierarchy 316 3.39 0.09 1.53 0.00 6.00 -0.12 -0.24 
CPS 316 4.13 0.08 1.43 0.00 6.00 -0.76 -0.16 
DRS 316 1.58 0.12 2.21 0.00 12.00 1.84 3.51 
DRS (Square Root) 316 0.86 0.05 0.92 0.00 3.46 0.58 -0.79 
NSS 316 0.59 0.09 1.53 0.00 8.00 2.93 8.42 
NSS (Square Root) 316 0.31 0.04 0.71 0.00 2.83 2.10 3.07 
ABS 316 2.39 0.14 2.42 0.00 12.00 1.26 2.00 
ABS (Square Root) 316 1.23 0.05 0.94 0.00 3.46 -0.05 -1.07 
CHESS 316 0.32 0.04 0.64 0.00 4.00 2.45 7.06 
CHESS (Square Root) 316 0.27 0.03 0.49 0.00 2.00 1.43 0.57 
Pain  313 0.45 0.04 0.75 0.00 3.00 1.58 1.57 
Pain (Square Root) 313 0.36 0.03 0.56 0.00 1.73 1.04 -0.63 
Running head: PSYCHOTROPIC MEDICATION PATTERNS 48 
Mean Calculations and Descriptives 
 The mean number of psychotropic medications varied across each point in time (M = 
2.18, M = 2.29, and M = 2.04 for F1, C1, and C2, respectively; Table 3). Figure 6 displays an 
increase from F1 to C1 and a small decrease from C1 to C2.  
Table 3 Mean Calculations of Psychotropic Medication Usage. 
Mean Calculations of Psychotropic Medication Usage 
      95% Confidence Interval  
Point in Time M SD Lower Bound Upper Bound 
Total psych F1 2.1795 2.0936 1.7075 2.6515 
Total psych C1 2.2949 1.8099 1.8868 2.7029 
Total psych C2 2.0385 1.7014 1.6549 2.4221 
 
 
Figure 6. The mean number of psychotropic medications across F1, C1, and C2. 
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Correlational Analysis 
The relationships between each predictor and psychotropic medication were examined 
using Pearson correlations (Table 4). There were consistent positive relationships between the 
total number of psychotropic medications and the total number of psychiatric diagnoses, total 
medical diagnoses and depression symptoms. The total number of psychiatric diagnoses was the 
most highly correlated with psychotropic medication (r = .24; p < .01), followed by total medical 
diagnoses (r = .17; p < .01), and depression symptoms (r = .12; p < .05). Only adaptive function 
was negatively correlated with the total number of psychotropic medications (r = -.12; p < .05). 
Therefore, an increase on the adaptive functioning scale was associated with a decrease in 
psychotropic medications. However, the adaptive functioning scale is inverted, and therefore, 
better adaptive functioning was associated with a higher number of psychotropic medications. 
Age, cognitive performance, CB, pain, negative symptoms, and health instability were not 
associated with the total number of psychotropic medications (p > .05).  
Table 4 also included correlations between the variables and other potential predictors 
(not including psychotropic medication). Consistent positive relationships were found between 
aggression and total number of psychiatric diagnoses (r = .19; p < .01), depression symptoms (r 
= .43; p < .01), pain (r = .15; p < .01), negative symptoms (r = .22; p < .01), and health 
instability (r = .27; p < .01). Therefore, individuals with more psychiatric diagnoses, depression 
and negative symptoms, pain, and health instability tended to have higher levels of aggression. In 
contrast, age was inversely related to aggression (r = -.11; p < .05).  
Depression symptoms were also highly correlated across several variables. In addition to 
the high correlation with aggression, depression symptoms were positively correlated with the 
number of psychiatric diagnoses (r = .32; p < .01), pain (r = .30; p < .01), negative symptoms (r 
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= .36; p < .01), and health instability (r = .20; p < .01). Therefore, individuals with higher levels 
of CB, pain, negative symptoms, health instability and psychiatric diagnoses were more likely to 
exhibit depression symptoms when compared to individuals with lower scores on the ABS. 
Lastly, depression symptoms were negatively correlated with cognitive performance. Therefore, 
as cognitive performance increased, depression symptoms decreased (r = -.11; p < .05).  
Overall, the correlation analysis demonstrated that only certain characteristics were 
correlated with the total number of psychotropic medications. Further, aggression and depression 
symptoms were the variables most frequently correlated significantly with other variables. 
Nonetheless, all the significant correlations were between -.1 and .43. Therefore, the significant 
relationships between all the variables were considered to be only weak or moderate in strength 
(Agolu, 2018).  
Table 4 Pearson Correlations of Potential Variables. 
Pearson Correlations of Potential Variables 
Variables 1 2 3 4 5 6 7 8 9 10 11 
1. Total 
number of 
psych meds 
- -.10 .24** .17** -.07 .10 -.12* .12* .01 .05 .06 
2. Age - - -.04 .01 .08 -.11* .03 -.03 -.03 -.12* .13* 
3. Total 
number of 
diagnoses 
- - - -.04 -.11* .19** .03 .32** .03 .23** .12* 
4. Total 
medical 
diagnoses 
- - - - .12* .03 .07 -.03 .02 .01 -.03 
5. CPS - - - - - -.10 .02 -.11* -.09 .08 -.05 
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6. ABS - - - - - - -.02 .43** .15** .22** .27** 
7. IADL-
Perf 
- - - - - - - .01 .04 .05 -.16** 
8. DRS - - - - - - - - .30** .36** .20** 
9. Pain - - - - - - - - - .18** .23** 
10. NSS - - - - - - - - - - .22** 
11. CHESS - - - - - - - - - - - 
Note. *p < .05. **p < .001 
 
Examining potential variables compared to the interRAI-ID. The total number of 
psychiatric diagnoses was compared to NSS and DRS to ensure an appropriate measure was used 
to capture mental health status (Table 5). Overall, total number of psychiatric diagnoses appeared 
to be more normally distributed (skewness= 1.57; kurtosis= 1.65) when compared to NSS 
(skewness= 2.93; kurtosis= 8.42) and DRS (skewness= 1.84; kurtosis= 3.51). Bivariate 
correlations were conducted to compare the total number of psychiatric diagnoses to DRS and 
NSS (Table 5). Kendall’s tau correlations were examined. NSS and DRS were significantly 
correlated with one another at a lower level (τ = 0.251, p = .000; τ = 0.331, p = .000, 
respectively). Given that the variables were only moderately correlated, the total number of 
psychiatric diagnoses was considered as a potential predictor of the total number of psychotropic 
medications.  
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Potential health status variables were also examined to ensure the most appropriate health 
status was selected for the model. Bivariate analyses were used to compare the health status 
variables for the total number of medical diagnoses, pain scale and CHESS. Kendall’s tau 
correlations were examined to compare Pain and CHESS to the total number of medical 
diagnoses (Table 6). Overall, the total number of medical diagnoses was not significantly 
correlated with either Pain or CHESS (p > .05). Given that the total number of medical diagnoses 
was fairly normally distributed (Table 3), this variable was included as a potential measure of 
health status. 
CB variables were investigated to determine the most appropriate variables to include. 
Bivariate analyses were conducted to compare the total behaviour composite (based on the BPI) 
to the ABS. Kendall’s tau was calculated to compare ABS and total behaviour. ABS and the 
behaviour composite had a strong, significant correlation (τ = .633, p = .000; Table 7). In 
addition, the composite CB variable that included physical abuse for C1 and C2 was compared to 
the ABS for C1 and C2, respectively. Both variables were also highly correlated (τ = .705, p = 
.000 for C1; τ = .640, p = .000 for C2). Given the strong correlation, the ABS was the only 
measure used for measuring CB, as ABS is a validated measure (Martin et al., 2007). 
Table 5Kendall’s Tau Correlations for Mental Health status. 
Kendall’s Tau Correlations for Mental Health Status 
Variable 
1. Total psychiatric 
diagnoses 2. DRS 3. NSS 
1. Total psychiatric 
diagnoses 
- .241** .180** 
2. DRS 
- - .241** 
3. NSS 
- - - 
Note. *p < .05. **p < .001    
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Table 6 Kendall’s Tau Correlations for Health Status. 
Kendall’s Tau Correlations for Health Status 
Variable 
1. Total medical 
diagnoses 2. Pain 3. CHESS 
1. Total medical 
diagnoses 
- .042 -.017 
2. Pain 
- - .213** 
3. CHESS 
- - - 
Note. *p < .05. **p < .001  
 
Table 7Kendall’s Tau Correlations for Challenging Behaviour. 
Kendall’s Tau Correlations for Challenging Behaviour 
Variable 1. Total behaviour composite  2. ABS 
1. Total behaviour 
composite 
- .633** 
2. ABS 
- - 
Note. *p < .05. **p < .001 
 
Multilevel Model 
 Multilevel modeling of psychotropic medication usage was conducted over four steps to 
represent a picture of the transition from the institution to community settings. The first step 
included creating a model that represented the person-to-person changes in psychotropic 
medication usage over time. Second, a model was formed to characterize the total number of 
psychotropic medications over time. Third, relevant covariates and demographics were entered 
as fixed effect variables to predict psychotropic medication changes. Lastly, substantive 
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predictors that were the primary targets for analysis were entered to examine polypharmacy 
dynamics across the study period.  
 Null model. For the fixed effects, the intercept was significant with an estimate of 2.317 
(p = .000), thereby indicating that the model converged (Table 8). The estimates of the 
covariance parameters (Table 9) demonstrated that across F1, C1, and C2, participants were 
significantly different from one another (p = .000 for all three points in time). These results 
demonstrated that using a multilevel model was appropriate as individuals in this population 
were receiving statistically different numbers of psychotropic medications across each point in 
time. Table 14 displays that -2 Log Likelihood, the AIC, and the BIC. These values are 
1178.310, 1190.310, and 1212.833, respectively. These values were compared to later models to 
ensure that the model fit with the data more effectively as predictors were added. Figure 1 
displays the histogram of the residuals in the null model, which appeared to be positively 
skewed. However, skewness and kurtosis scores were acceptable, with values of 0.603 and -
0.188 respectively. Only participant 211 was considered an outlier based on the boxplot (Figure 
1).  
Table 8 Type III Tests of Fixed Effects for the Null Model.  
Type III Tests of Fixed Effects for the Null Model  
Fixed Effects   
Variable Estimate SE df t p 
Intercept 2.317 0.148 123.865 15.628 .000 
Note. *p < .05. **p < .001 
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Table 9 Estimates of Covariance Parameters of the Null Model. 
Estimates of Covariance Parameters of the Null Model 
Random Effects 
    Estimate SE Wald Z p 
Repeated Measures Index 1 4.680 0.612 7.649 .000** 
 Index 2 3.232 0.419 7.710 .000** 
 Index 3 2.702 0.401 6.744 .000** 
 TPH rho 1 0.680 0.043 15.706 .000** 
  TPH rho 2 0.592 0.073 8.106 .000** 
Note. *p < .05. **p < .001 
 Null growth model. The fixed results are listed in Table 10. When individuals moved 
from the facility to the community, there was not a significant change in the number of 
psychotropic medications used across settings (p = 0.783). However, over time in the 
community, the number of psychotropic medications decreased by 0.285 (p = 0.047). The 
random effects summary is listed in Table 11. Participants were significantly different from one 
another in F1 and C1 (Estimate = 4.481, p = 0.000; Estimate = 2.554, p = 0.000 respectively). 
Further, TPH rho 1 and 2 were also statistically significant (Estimate = 0.692, p = 0.000; 
Estimate = .843, p = .031, respectively). The variance over time (e.g., the slope of each 
participant’s trajectory) was significantly different across participants (Estimate = 0.398; p = 
.031). The -2 Log Likelihood, AIC, and BIC values can be found in Table 14 (1170.572, 
1188.572, and 1222.430, respectively). Both -2 Log Likelihood and AIC were lower in the null 
growth model, suggesting a better fit when compared to the null model. The residuals of the null 
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were positively skewed (Figure 2) but skewness and kurtosis values were 0.143 and 0.285, 
respectively.  
Table 10 Type III Tests of Fixed Effects for the Null Growth Model. 
Type III Tests of Fixed Effects for the Null Growth Model 
Fixed Effects   
Variable Estimate SE Df t p 
Intercept 2.317 0.148 123.865 15.628 .000** 
FC Change 0.042 0.151 133.873 0.275 .783 
CC Change -0.285 0.143 195.348 -1.995 .047* 
Note. *p < .05. **p < .001 
Table 11 Estimates of Covariance Parameters of the Null Growth Model. 
Estimates of Covariance Parameters of the Null Growth Model 
Random Effects 
    Estimate SE Wald Z p 
Repeated 
Measures Index 1 4.481 0.580 7.730 .000** 
 Index 2 2.554 0.444 5.747 .000** 
 Index 3 1.225 0.657 1.864 .062 
 TPH rho 1 0.692 0.052 13.234 .000** 
 TPH rho 2 0.902 0.261 3.454 .001** 
Time Variance 0.398 0.184 2.162 .031* 
Note. *p < .05. **p < .001 
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 Base model with covariates. Similar to the previous models, from F1 and C1 to C2 (CC 
Change), the total number of psychotropic medications decreased by 0.279 (p = .033; Table 12). 
Age and adaptive functioning were not significant predictors of psychotropic medication usage 
(p = .077 and .915). In terms of the random effects, individuals were significantly different from 
one another at F1 and C1 (Estimate = 4.446, p = .000; Estimate = 2.760, p = .000; Table 13), 
which indicated that the use of the multilevel model was appropriate to implement. TPH rho 1 
and 2 were also significant (Estimate = .783, p = .000; Estimate = .843, p = .000, respectively). 
The -2 Log Likelihood, AIC, and BIC were 1025.058, 1047.058, and 1087.427, respectively 
(Table 14). Therefore, all three criteria were lower than the null growth model, suggesting that 
adding these covariates significantly improved the fit of the growth model and contributed 
meaningfully to the person-to-person estimates of change over time. The residuals of the base 
model with covariates were examined. The histogram (Figure 3) was normally distributed, with 
skewness and kurtosis values of 0.616 and 0.438. Only one case (211) was considered an outlier 
based on the boxplot of the residuals (Figure 3).  
Table 12 Type III Tests of Fixed Effects for the Base Model with Covariates. 
Type III Tests of Fixed Effects for the Base Model with Covariates 
Fixed Effects   
Variable Estimate SE df t p 
Intercept 2.578 0.205 110.431 12.593 .000** 
FC Change -0.106 0.146 117.244 -0.726 .469 
CC Change -0.279 0.129 175.612 -2.154 .033* 
Age -0.034 0.019 124.651 -1.786 .077 
Adaptive 
functioning -0.001 0.007 164.659 -0.107 .915 
Note. *p < .05. **p < .001 
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Table 13 Estimates of Covariance Parameters of the Base Model with Covariates. 
 Estimates of Covariance Parameters of the Base Model with Covariates 
Random Effects  
    Estimate SE Wald Z p 
Repeated Measures Index 1 4.446 0.631 7.050 .000** 
 Index 2 2.760 0.516 5.351 .000** 
 Index 3 1.692 1.180 1.435 .151 
 TPH rho 1 0.783 0.054 14.624 .000** 
 TPH rho 2 0.843 0.300 2.807 .005* 
Time Variance 0.273 0.298 0.915 .360 
Note. *p < .05. **p < .001 
Base model with covariates and substantive predictors. The base model was 
repeatedly evaluated with each predictor entered into the model one at a time. Certain variables 
(i.e., CPS, total diagnoses, NSS), were entered into the model without their interactions. NSS 
was entered as a fixed variable (at F1) rather than a repeated measure (at F1, C1, and C2) due to 
the model not converging. The results from each of these models can be found in Table 15. DRS, 
ABS, sex, total medical diagnoses, and the interactions of each of these variables with FC change 
and CC change did not produce any significant relationships (p > .05) in relation to psychotropic 
medication use or change in use over time. In contrast, CPS, CHESS, CHESS interactions with 
FC change, Pain, and total psychiatric diagnoses were significant predictors of the total number 
of psychotropic medications when inputted into the base model. 
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CPS, the total number of psychiatric diagnoses, and pain were significant predictors, but 
only when examining the variable without its interactions with FC and CC change. Every one 
point of CPS was associated with 0.142 fewer psychotropic medications (t = -2.610, df = 
204.528, p = .01; Table 15). Therefore, when individuals displayed more impairments in 
cognitive performance (i.e., short-term memory, decision-making, expression, and self-
performance), psychotropic medication usage was lower. The total number of psychiatric 
diagnoses significantly predicted psychotropic medication usage (Table 15). Each one-point 
increase in total psychiatric diagnoses was associated with a 0.300 increase in total psychotropic 
medications (t = 2.763, df = 228.078, p = .006). Pain was also a significant predictor of the total 
number of psychotropic medications (Table 15). An increase of one point on the pain scale was 
associated with an increase in 0.606 psychotropic medications (t = 2.534, df = 110.173, p = 
.013).  
 The CHESS significantly predicted psychotropic medications; however, the influence of 
this measure varied depending on the setting and time. When examining the CHESS independent 
of interactions with FC and CC changes, a 1 unit increase on the CHESS was associated with a 
0.785 increase in psychotropic medications (t = 3.010, df = 104.105, p = .003; Table 15). 
However, this relationship differed when examining the interaction between CHESS and certain 
points in time. When individuals transitioned from the facility to the community, an increase in 
one point on the CHESS (less health stability; worse health) resulted in a decrease in 0.733 
psychotropic medications (t = -2.617, df = 141.791, p = .01). These findings suggested that when 
individuals were moving from the facilities to the community, worse health was associated with 
a decrease in the total number of psychotropic medications. The interaction between CHESS and 
CC change was not significant (p = .834).  
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 The information criterion (-2 Log Likelihood, AIC, and BIC) were compared across each 
potential model (Table 16). The information criterion range between 1005.895 to 1013.952, 
10031.939 to 1041.952, and 1075.388 to 1090.636 for -2 Log Likelihood, AIC, and BIC 
respectively. CPS, Total Psych Diagnoses, CHESS (with interactions), and pain (with 
interactions) appeared to be the models with the lowest -2 Log Likelihood (1007.939, 1007.516, 
1007.867, and 1005.895, respectively), AIC (1031.939, 1031.516, 1035.876, 1033.895), and BIC 
scores (1075.811, 1075.388, 1087.051, and 1085.079, respectively). As such, CPS, total 
psychiatric diagnoses, CHESS + interactions, and Pain + interactions were included in the final 
model. 
Table 14 Information Criteria for All Models.. 
 Information Criteria for All Models 
Information Criteria Null Model 
Null Growth 
Model 
Base Model with 
Covariates 
Final Model 
-2 Log Likelihood 1178.310 1170.572 1025.058 988.341 
AIC 1190.310 1188.572 1047.058 1026.341 
BIC 1212.883 1222.430 1087.427 1095.804 
 
Table 15 Potential Predictors and their Interactions with Time Variables.. 
Potential Predictors and their Interactions with Time Variables 
Variable + Base Model Estimate SE df t p 
CPS 
-0.144 0.128 110.050 -1.125 .263 
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CPS * FC Change 
-0.014 0.131 122.891 -0.107 .915 
CPS * CC Change 
0.041 0.096 160.452 0.428 .669 
CPS 
-0.142 0.055 204.528 -2.610 .01* 
DRS 
0.023 0.118 107.994 0.195 .846 
DRS * FC Change 
0.041 0.119 113.854 0.342 .733 
DRS * CC Change 
-0.097 0.062 166.225 -1.566 .119 
Total Psych Diagnoses 
0.300 0.109 228.078 2.763 .006* 
ABS 
0.023 0.068 104.165 0.337 .737 
ABS * FC Change 
0.005 0.077 141.915 0.059 .953 
ABS * CC Change 
-0.037 0.056 163.848 -0.649 .517 
Pain 
0.606 0.239 110.173 2.534 .013* 
Pain * FC Change 
-0.503 0.263 137.698 -1.911 .058 
Pain * CC Change 
-0.104 0.177 152.853 -0.587 .558 
CHESS 
0.785 0.261 104.105 3.010 .003* 
CHESS * FC Change 
-0.773 0.295 141.791 -2.617 .010* 
CHESS * CC Change 
-0.038 0.193 146.313 -0.198 .843 
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Total Medical Diagnoses 
0.204 0.198 116.789 1.033 .304 
Total Med Diagnoses * FC 
Change 
0.011 0.194 128.380 0.054 .957 
Total Med Diagnoses * CC 
Change 
0.055 0.160 153.641 0.347 .729 
NSS- Static 0.169 0.190 129.684 0.893 .374 
Sex -0.033 0.416 109.501 -0.080 .936 
Sex * FC Change 0.106 0.305 118.445 0.348 .728 
Sex * CC Change -0.310 0.261 171.444 -1.192 .235 
Note. *p < .05. **p < .001 
Table 16 Information Criterion for the Base Model with Substantive Predictors. 
 Information Criterion for the Base Model with Substantive Predictors 
  Information Criterion 
Models 
-2 Log 
Likelihood AIC BIC 
CPS + Interactions 1007.759 1035.759 1086.943 
CPS 1007.939 1031.939 1075.811 
DRS + Interactions 1011.452 1039.452 1090.636 
NSS fixed measure 1013.838 1037.838 1081.710 
Total Psych Diagnoses 1007.516 1031.516 1075.388 
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ABS + Interactions 1013.952 1041.952 1093.136 
Pain + Interactions 1007.867 1035.867 1087.051 
CHESS + Interactions 1005.895 1033.895 1085.079 
Total Medical Diagnoses + Interactions 1010.794 1038.794 1089.978 
Note. *p < .05. **p < .001 
Final model. Age and adaptive functioning were entered as covariates. CPS, total 
psychiatric diagnoses, CHESS, CHESS * FC Change, CHESS * CC Change, Pain, Pain * FC 
Change, and Pain * CC Change were entered as potential predictors. The distribution of the final 
model was examined (Figure 4). The histogram of the residuals (Figure 4) were normally 
distributed, with skewness, and kurtosis values were 0.588 and 0.299, respectively. The boxplot 
also demonstrated only a few outliers (case 211, 313, and 146). Table 17 displays the fixed 
effects of the final model. When individuals transitioned from the facility to the community, 
psychotropic medications decreased by 0.389 (p = .012). Further, when individuals were visited 
for follow-up in the community, psychotropic medications also decreased by 0.261 (p = .045). 
Age and adaptive functioning were not significant predictors of psychotropic medication usage 
(p = .114, p = .875).  
Table 17 Type III Tests of Fixed Effects for the Final Model. 
 Type III Tests of Fixed Effects for the Final Model 
Fixed Effects   
Variable Estimate SE df t p 
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Intercept 2.683 0.207 129.933 12.946 .000** 
FC Change -0.389 0.153 120.034 -2.543 .012* 
CC Change -0.261 0.129 172.085 -2.018 .045* 
Age -0.030 0.019 120.420 -1.591 .114 
Adaptive functioning -0.001 0.007 161.335 -0.157 .875 
CPS -0.132 0.053 205.325 -2.463 .015* 
Total psychiatric 
diagnoses 0.271 0.108 227.292 2.517 .013* 
CHESS 0.639 0.260 103.794 2.461 .015* 
CHESS * FC Change -0.765 0.293 137.806 -2.612 .010* 
CHESS * CC Change 0.077 0.200 151.267 0.385 .701 
Pain 0.512 0.235 104.774 2.183 .031* 
Pain * FC Change -0.416 0.260 133.476 -1.602 .111 
Pain * CC Change -0.038 0.185 160.735 -0.204 .838 
Note. *p < .05. **p < .001 
Table 14 displays the information criteria for the final model. Both the AIC and the -2 
Log Likelihood decreased when compared to the earlier models, suggesting an improvement in 
the fit of the model. The BIC increased by 8.377 when compared to the base model. However, 
the increase in the BIC was by less than 10, which provided support for the final model 
representing the best fit for the growth model. Table 18 demonstrated that at F1, C1, TPH rho 1 
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and TPH rho 2, participants differed significantly from one another (p = .000 for F1, C1, and 
TPH rho 1, TPH rho 2 = .013). Therefore, using a multilevel analysis was appropriate for this 
final model as participants were significantly distinct from one another across various points in 
time. 
Table 18 Estimates of Covariance Parameters of the Base Model with Covariates.. 
Estimates of Covariance Parameters of the Base Model with Covariates 
Random Effects 
    Estimate SE Wald Z p 
Repeated Measures Index 1 3.985 0.567 7.035 .000 
 Index 2 2.535 0.514 4.936 .000 
 Index 3 1.577 1.255 1.257 .209 
 TPH rho 1 0.789 0.060 13.224 .000 
 TPH rho 2 0.865 0.348 2.483 .013 
Time Variance 0.275 0.317 0.869 .385 
Note. *p < .05. **p < .001 
CPS was a significant predictor of psychotropic medication, in that, when CPS increased 
by 1-unit, psychotropic medication usage decreased by 0.132 (p = .015; Table 17). No significant 
relationships were found when examining CPS with either time variables (p > .05). The 
predictive values were visually displayed across time when CPS was binned into low, medium 
and high sections (intact, mild to moderate, moderate to severe; Figure 7). The lowest trend line 
represented the highest CPS score, which suggested that when individuals had a higher CPS 
PSYCHOTROPIC MEDICATION PATTERNS  66 
score (moderate to severe), the mean predictive value of psychotropic medications was lower 
(Figure 7). Lastly, the confidence intervals ranged depending on CPS score. Individuals in the 
range of intact to intact borderline tended to have the largest variability in terms of psychotropic 
medications.  
 
 
Figure 7. Mean plot of the predictive values over time for CPS. CPS was divided into three 
categories. 
Total psychiatric diagnoses displayed a positive correlation with psychotropic 
medication. When the number of psychiatric diagnoses increased by 1, psychotropic medication 
increased by 0.271 (p = .013; Table 17). These results were also demonstrated by the mean plot 
of binned total diagnoses over time (no diagnosis, one diagnosis, more than one diagnosis; 
Figure 8). The highest trend line was the “more than one diagnosis” category. Therefore, 
individuals with more than one diagnosis were more likely to receive a higher number of 
psychotropic medications when compared to the no diagnosis and one diagnosis subgroups. In 
C2, large confidence intervals were present when examining the predictive mean number of 
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psychotropic medications for individuals with more than one psychiatric diagnosis. This finding 
may have emerged due to the reduction in the number of participants from 120 to 78.  
 
Figure 8. Mean plot of the predictive values over time for total psychiatric diagnoses. 
 
Pain displayed a positive relationship between psychotropic medication usage. When 
Pain increased by 1, psychotropic medication increased by 0.512 (p = .031; Table 17). These 
results were visually displayed when Pain was divided into no pain and pain subcategories 
(Figure 9). The pain category produced the higher trendline across F1, C1, and C2 when 
compared to the no pain category. No significant relationships were found when Pain was 
examined with its interactions with the time variables (p > .05). 
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Figure 9. Mean plot of the predictive values over time for pain. 
The relationship between CHESS and psychotropic medication varied across settings and 
over time. Overall, when the CHESS score increased by 1, (the participant had worse health) 
psychotropic medication increased by 0.639 (p = .015; Table 17). This relationship was not 
consistent when examining the interactions of CHESS with time. When individuals transitioned 
from the facility to the community (FC Change), an increase in the CHESS by 1 resulted in a 
decreased in psychotropic medication usage by 0.765 (p = .010). Therefore, when individuals 
exhibited more health stability (better health) during this transition, the number of psychotropic 
medications was higher. CHESS and CC change was not significant (p = .701). These results 
were also demonstrated by the mean plot (Figure 10). The graph suggests that in F1 when 
CHESS was “unstable”, the predictive number of psychotropic medications was higher than “not 
at all unstable”. However, individuals with an unstable CHESS and those that were not at all 
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unstable appeared to have similar predictive values in C1 and C2. These findings aligned with 
Table 17, which indicated that the CHESS interaction with FC Change was inversely related to 
psychotropic medication usage (Estimate = -0.765, p = .010).  
 
 
Figure 10. Mean plot of the predictive values for CHESS over time. 
Post Hoc Analyses 
 In order to further investigate the anomalous finding that CB did not predict the total 
number of psychotropic medications in our sample, post hoc analyses were conducted to 
examine the differences between the ABS (used in this study) and the BPI (used in other studies) 
in C1. First, a Pearson correlation analysis was conducted to examine the relationship between 
the BPI and the ABS at C1. The BPI and the ABS at C1 were not significantly correlated (p = 
.099; Table 19).  
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Table 19 Pearson Correlations of ABS, BPI, and Psychotropic Medications at C1. 
Pearson Correlations of ABS, BPI, and Psychotropic Medications at C1 
Variables 1 2 3 
1. ABS - .155 .229* 
2. BPI - - .304** 
3. Total psych meds - - - 
Note. *p < .05. **p < .001 
Secondly, interquartile ranges were examined across BPI and ABS (Figure 11, Figure 12, 
Table 20). The interquartile ranges for ABS were 0, 2, and 4 for 25%, 50%, and 75%, 
respectively. For the BPI scale, the 25% score was 8, followed by 17 and 31 for the 50% and 
75% scores, respectively. These findings suggested that there were discrepancies across the 
distribution of the variables. For the ABS, the 25% quartile was 0. This result showed that 25% 
of the participants received scores of zero on the ABS. In contrast, the 25% quartile for the BPI 
was 8, which demonstrated that the lowest scoring individuals did not receive mostly scores of 0 
on the BPI. For ABS, the median was 2 on the 12-point ABS scale. Conversely, for the BPI, the 
median score was 17 on the 66-point BPI measure. Lastly, the 75% quartile score for ABS was 4. 
In contrast, the 75% score on the BPI was 31. These findings emphasized that participants 
overall scored lower on the ABS than the BPI. This analysis lends supports to the lack of 
correlation across these scales, which indicated that the ABS did not measure CB in a way that 
aligned with the BPI.  
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Figure 11. Boxplot of ABS at C1. 
 
Figure 12. Boxplot of BPI at C1. 
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Table 20 Interquartile Ranges of ABS and BPI at C1. 
Interquartile Ranges of ABS and BPI at C1 
  Scales 
   ABS BPI 
N 119 115 
Minimum 0 0 
Maximum 12 66 
Percentiles 
25% 0 8 
50% 2 17 
75% 4 31 
 
Summary of Findings 
The findings of the multilevel model demonstrated that some that some individual 
characteristics contributed positively or negatively to the total number of psychotropic 
medication while others were not significant predictors.  
Health instability, pain, and total psychiatric diagnoses predicted higher numbers of 
psychotropic medication. Health instability contributed most to the model, in that, when health 
instability increased, psychotropic medications increased by 0.639. Pain also contributed to 
model. When pain symptoms went up by one unit, medication usage increased by 0.512. Total 
psychiatric diagnoses positively influenced psychotropic medications. When an individual had 
one more diagnosis, psychotropic medications increased by 0.271. Given that health instability, 
pain, and psychiatric diagnoses were scored on a scale from zero to four (see measures), it can be 
concluded that health instability and pain influenced the model more than the number of 
psychiatric diagnoses.  
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Other individual characteristics were inversely related to the total number of psychotropic 
medications. The interaction between health instability and facility to community change 
negatively predicted the number of psychotropic medications. Therefore, when health instability 
increased (participants had worse health) as individuals transitioned from the facility to the 
community by a unit of one, psychotropic medication decreased by 0.765. This finding 
demonstrated that the influence of health instability changed across time and settings. Lastly, 
cognitive performance was inversely related to psychotropic medication. When the cognitive 
performance scale increased by one (individuals had lower cognitive performance), psychotropic 
medication decreased by 0.132. However, the health instability measure was scored from zero to 
four while cognitive performance was evaluated from zero to six. The differences in scales 
should be noted when considering the influences of each predictor. 
Lastly, certain characteristics did not predict the number of psychotropic medications 
despite being expected to. In particular, aggression did not influence the model. Similarly, 
although the number of psychiatric diagnoses influenced the model, negative and depression 
symptoms did not. These findings may have emerged due to the types of measures that were 
used in the study. 
Discussion 
 This study examined changes in psychotropic medication usage among a group of 
individuals with ID who experienced deinstitutionalization in Ontario. Specifically, this study 
evaluated individual characteristics that predicted the number of psychotropic medications 
prescribed. Three research questions were investigated using descriptive summaries, 
correlational analyses, and multilevel models. This discussion outlines the answers to these 
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research questions, the wider implications of the results, strengths and limitations of the study, 
and steps for future research.  
 Descriptive statistics were examined to evaluate the mean number of psychotropic 
medications at each point in time. Correlational analyses were conducted to investigate any 
relationships between individual characteristics and psychotropic medication usage. Multilevel 
analyses were implemented to examine predictors of the number of psychotropic medications 
over time. The final multilevel model was developed from four main models. The first model, or 
null model, only consisted of the outcome variable, the total number of psychotropic 
medications. The second model (null growth model) included the FC and CC change variables 
entered as fixed effects, and time (F1, C1, C2) entered as a random effect. The base model added 
age and adaptive functioning as fixed effects. Base models with substantive predictors were 
tested, which included entering one variable and its interaction with FC and CC changes one at a 
time into the model. This process was completed for each potential predictor. The individual 
characteristics that did not contribute to this particular model were CB, the total number of 
medical diagnoses, depression symptoms, negative symptoms, adaptive functioning, age, and 
sex. The final model was created based on the information criterion values and the significance 
of predictors. This final model included age, adaptive functioning, health instability, the 
interactions between health instability and FC and CC changes, Pain, the interactions between 
Pain and FC and CC changes, and total psychiatric diagnoses as fixed effects. Cognitive 
performance, health instability, the interaction between health instability and FC Change, Pain, 
and the total number of psychiatric diagnoses predicted the number of psychotropic medications.  
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Research Question 1: What is the mean number of psychotropic medication usage across 
each point in time? 
 The means of psychotropic medication frequencies were high across each point in time in 
this sample. These findings suggested that after relocating to the community, the number of 
psychotropic medications increased but over time, psychotropic medication usage decreased 
below the frequencies at the facilities. Nonetheless, these results emphasized the high number of 
psychotropic medications currently prescribed to individuals with ID in Ontario.  
The high numbers of psychotropic medications prescribed to this population aligned with 
previous studies that examined psychotropic medication usage among individuals with ID who 
experienced deinstitutionalization (McGillivray & McCabe, 2005; Nottestad & Linaker, 2003). 
Nottestad and Linaker (2003) examined psychotropic medication trends following 
deinstitutionalization. In both 1987 and 1995, the authors found that 50% and 54% of the 
participants were prescribed psychotropic medications, respectively. McGillivray and McCabe 
(2005) examined psychotropic medications among individuals living in the community and 
institutions in 1993 and 2000. The authors determined that the number of psychotropic 
medications per person ranged from 1.4 to 1.72. Both the current study and the McGillivray and 
McCabe (2005) study included pro re nata (PRN; as needed) psychotropic medications in the 
analyses. Therefore, the slightly higher number of psychotropic medications in the current 
sample may be linked to the fact that individuals who were still residing in Ontario institutions 
may have presented with a higher number of health and mental health challenges when compared 
to the participants in the McGillivray and McCabe (2005) study, in that this more recent sample 
had increased access to healthcare, mental healthcare, and medication than their counterparts 
from roughly a decade earlier. 
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The changes in the number of psychotropic medications before and after 
deinstitutionalization varied depending on the study (McGillivray & McCabe, 2005; Nottestad & 
Linaker, 2003). McGillivray and McCabe (2005) indicated that in 1993, individuals living in the 
institutions and community were prescribed, on average, 1.4 and 1.45 psychotropic medications, 
respectively. In the 2000 sample, individuals who resided in the institution were prescribed, on 
average, 1.72 psychotropic medications while individuals living in the community were 
prescribed an average of 1.51 psychotropic medications. These findings suggested increased total 
numbers of psychotropic medication among individuals residing in facilities when compared to 
community living. However, the current study found that an initial increase in the number of 
psychotropic medications followed by a subsequent decrease in the number of psychotropic 
medications over time in the community. The initial increase in the number of psychotropic 
medications may have occurred due to individuals experiencing the major life change of 
relocating to community settings. However, over time, the total number of psychotropic 
medications decreased, possibly due to individuals adapting to their new community settings. In 
contrast, Nottestad and Linaker (2003) did not find any changes in either the frequency of people 
using psychotropic medications or dosage of psychotropic medications following relocation to 
community settings. These differences between the current study and past studies may have 
occurred as psychotropic medications were examined across three points in time rather than two. 
It is possible that, if previous studies had included additional points in time, they may have 
detected similar changes as individuals adjusted to community settings. 
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Research Question 2: What is the relationship between psychotropic medication, age, sex, 
cognitive performance, adaptive behaviour, medical diagnoses, serious health conditions, 
pain, psychiatric diagnoses, depression, pain, and challenging behaviour?  
 To examine the relationships between psychotropic medications and the potential 
variables of interest, Pearson correlations were conducted. The total number of psychiatric 
diagnoses, total medical diagnoses, and adaptive functioning were significantly correlated to the 
total number psychotropic medications. Age, adaptive functioning, cognitive performance, CB, 
pain, anhedonia, and health instability were not significantly correlated with the number of 
psychotropic medications.  
In the current study, demographic variables, such as age and sex, were not significantly 
correlated with the number of psychotropic medications. The lack of correlation between sex and 
psychotropic medication aligned with previous studies as both Deb et al. (2015) and O’Dwyer et 
al. (2016) determined that sex was not significantly associated with daily antipsychotic dosages 
and polypharmacy status, respectively. Further, when Sheehan et al. (2015) conducted a 
univariable analysis, they determined that sex was not significantly associated with new 
antipsychotic prescriptions. In contrast, the lack of significant relationships between age and 
psychotropic medication usage did not align with previous studies (Deb et al., 2015; O’Dwyer et 
al., 2016; Sheehan et al., 2015). Deb et al. (2015) found that age was significantly correlated with 
daily antipsychotic dosage. Similarly, O’Dwyer et al. (2016) and Sheehan et al. (2015) 
determined that the age was significantly associated with polypharmacy status and new 
antipsychotic prescriptions, respectively. The findings from the current study may have differed 
from previous studies because age was entered as a continuous variable, rather than categorized 
into age groups.  
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Better adaptive functioning was positively correlated with polypharmacy. In contrast, 
cognitive functioning was not correlated with the total number of psychotropic medications. 
Better adaptive functioning (i.e., a lower score on the IADL-Perf) was associated with a higher 
number of psychotropic medications. However, the magnitude of this association was low (r = -
.12). These findings could suggest that, in this sample, individuals with more skills may not have 
experienced better mental health or benefitted from other types of therapy not accessible to those 
with fewer skills. Although Deb et al. (2015) did not examine adaptive functioning and cognitive 
performance, specifically, the authors determined that the severity of ID was not significantly 
correlated with antipsychotic dosage. Therefore, the findings in the current study may not have 
aligned with previous research due to the implementation of different measures.  
 The total number of medical diagnoses was positively correlated with polypharmacy, 
while health instability and pain were not. These findings suggested that individuals 
experiencing more medical challenges may be prescribed more psychotropic medications. 
Conversely, Sheehan et al. (2015) examined types of medical diagnoses, rather than a total 
number. The authors found that dementia was significantly associated with antipsychotic 
prescription incidence in univariable analyses, while epilepsy was not associated. Additionally, 
O’Dwyer et al. (2016) conducted bivariate analyses and found that specific chronic diseases (i.e., 
neurological, gastrointestinal, joint disease, endocrine disease, and hypertension) as well as 
reported pain were associated with polypharmacy. Therefore, both the current study and previous 
research demonstrated that, to a certain extent, psychotropic medication may be associated with 
health status variables.  
 Depression symptoms and the number of psychiatric diagnoses were significantly 
correlated with the total number of psychotropic medications. In contrast, anhedonia was not 
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significantly correlated with the number of psychotropic medications. Certain studies found a 
significant relationship between psychiatric diagnoses and psychotropic medication usage (e.g., 
O’Dwyer et al., 2016; Sheehan et al., 2015), while other studies did not (e.g., Deb et al., 2015; 
Perry et al., 2018). O’Dwyer et al. (2016) determined that mental health was significantly 
associated with polypharmacy status. Sheehan et al. (2015) also reported that severe mental 
illness, autism, depression, and anxiety were significantly associated with the incidence of 
antipsychotic medications in a univariable analysis. These findings were similar to the current 
study as the presence of mental health diagnoses was significantly associated with the total 
number of psychotropic medications. Further, scores on the DRS in the current study were 
significantly correlated with the total number of psychotropic medications, which is consistent 
with Sheehan et al. (2015)’s finding that the presence of depression was significantly associated 
with new antipsychotic prescriptions. In contrast, both Deb et al. (2015) and Perry et al. (2018) 
determined that psychiatric co-morbidity did not produce significant correlations with 
antipsychotic medication daily dosage and the use of psychotropic medication, respectively. 
Therefore, the results of these studies indicated that psychotropic medication may be prescribed 
to manage CB, rather than to treat psychiatric diagnoses (Deb et al., 2015; Perry et al., 2018). In 
contrast, the findings of O’Dwyer et al. (2016), Sheehan et al. (2015) and the current study 
suggest that, to a certain extent, a link between psychotropic medication and psychiatric 
diagnoses exist.  
 In the current study, the total number of psychotropic medications was not significantly 
associated with CB. Past research was not consistent with these findings as most demonstrated a 
significant correlation between CB and psychotropic medications (e.g., Bowring et al., 201a7; 
Deb et al., 2015). Bowring et al. (2017a) conducted Chi-square analyses to examine the 
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relationships between CB and psychotropic medication. CB was associated with psychotropic 
medication, as individuals with CB were twice as likely to be receiving psychotropic medication. 
Similarly, Deb et al. (2015) reported that the severity of aggressive behaviour, property 
destruction, and SIB were significantly correlated with daily antipsychotic dosage. The current 
study examined the total number of psychotropic medications, rather than antipsychotic dosage 
(Deb et al., 2015) or defined daily dosage (Bowring et al., 2017a), which could account for the 
different results. It is also possible that the psychotropic medication was having the desired effect 
of decreasing CB for some individuals, which could have impacted the results.  
Research Question 3: Does age, sex, cognitive performance, adaptive behaviour, medical 
diagnoses, serious health conditions, pain, psychiatric diagnoses, depression, pain, and 
challenging behaviour predict the total number of psychotropic medications? What are the 
relative influences of each variable? Do these influences change over time and across 
settings? 
With the use of a multilevel model, this study demonstrated that over time and across 
settings, the total number of psychotropic medications decreased. This change was shown by the 
total number of psychotropic medications decreasing when the time variables (FC and CC 
change) were included in the final model. Health instability, pain, and the total number of 
psychiatric diagnoses were positively related to psychotropic medication usage. Cognitive 
performance and the interaction between health instability and facility to community change 
were inversely related to polypharmacy. Lastly, aggression (as measured using the ABS) did not 
predict psychotropic medication, despite the hypothesis that it would (Bowring et al., 2017a; 
Nottestad & Linaker, 2003; Perry et al., 2018). Similarly, age, sex, adaptive functioning, 
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negative symptoms, depression symptoms and total number of medical diagnoses did not 
contribute to the model.  
In the final model, age and sex were not significant predictors of the total number of 
psychotropic medications. These findings differed from other studies that implemented 
multivariate analyses (Bowring et al., 2017a; Tsiouris et al., 2013). In 2017, Bowring et al. 
conducted a generalised linear model to examine the associations between psychotropic 
medications and certain individual characteristics. The authors found that older age predicted 
psychotropic medication usage (RR = 1.05, p < .001). Additionally, male sex increased the 
number of antipsychotic medications prescribed (RR = 2.42, p = .005). In contrast, Tsiouris et al. 
(2013) conducted a multivariate analysis and determined that sex did not significantly predict the 
number of psychotropic medications. Although age did not predict the incidence of psychotropic 
medication, individuals who had received medications previously had a decrease in rate of 6% 
medications per year. The current study examined the number of psychotropic medications, 
rather than only antipsychotic medications or the likelihood of starting psychotropic medications. 
Including specific classes of psychotropic medication or other outcome variables, such as 
psychotropic medication incidence, may have revealed different relationships.  
In the current study, better cognitive performance predicted higher numbers of 
psychotropic medication. Bowring et al. (2017a) determined that when severe-profound ID was 
included in a generalised linear model, this variable did not predict psychotropic medication 
usage. In contrast, O’Dwyer et al. (2017) examined psychotropic medication following 
deinstitutionalization among adults with ID with a multinomial logistic regression. The authors 
determined severe/profound ID significantly predicted psychotropic medication (odds-ratio; OR 
= 2.26; p = .032). Lastly, Tsiouris et al. (2013) determined that IQ differences did not increase 
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the number of psychotropic medications. Therefore, previous research was mixed in terms of the 
influence of individual characteristics on psychotropic medication, which aligned with the 
current study as cognitive performance was significant while adaptive functioning was not. 
However, given the lack of consistent measures, direct comparisons across studies were difficult, 
as these studies did not specifically use measures on the interRAI-ID.  
For the overall model, health instability predicted higher numbers of psychotropic 
medications. Therefore, the less stable an individual’s health (worse health), the more 
medications he or she was prescribed. O’Dwyer et al. (2016) examined various types of health 
conditions and found that neurological, endocrine, and hypertension diseases were significant 
predictors of polypharmacy in a multinomial logistic regression. Further, in 2000, Robertson et 
al. determined that certain health-related variables, such as not having impaired mobility and 
epileptic fits predicted antipsychotic and antianxiety psychotropic medications, respectively 
(Partial r = .1646; p < .0001; Partial r = .1192; p >.01). While the current study found that health 
instability positively predicted the total number of psychotropic medications, total medical 
diagnoses did not influence the overall model. Therefore, the presence of epilepsy, in contrast to 
Robertson et al. (2000), did not predict psychotropic medication. Variables relating specifically 
to health stability were not explored in other multivariate analysis studies (e.g., Bowring et al., 
2017a; O’Dwyer et al., 2017; Nottestad & Linaker, 2003; Robertson et al., 2000). 
The magnitude and direction of health instability as a predictor of polypharmacy changed 
across settings and over time. For the overall model, health instability positively predicted 
polypharmacy. In contrast, individuals who transitioned to the community with lower health 
instability (i.e., more stable health) were prescribed higher numbers of psychotropic medications. 
In 2000, Roberston et al. found that improved mobility predicted psychotropic medication usage. 
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Participants who engaged in CB with improved mobility could potentially be perceived as more 
dangerous to themselves, staff, and other residents. This finding could be linked to the current 
study, in that individuals with more stable health were more likely to be prescribed psychotropic 
medications when transitioning from the facility to the community than individuals with worse 
health. It is possible that if an individual had more severe health problems, he or she was less 
mobile and in turn, received less psychotropic medication to manage CB. Secondly, it is possible 
that individuals with worse health received less psychotropic medications when entering the 
community as health symptoms may have been treated more effectively in community settings 
due to the enhanced transition planning for this group of individuals.  
Pain was a positive predictor of psychotropic medication. This finding aligns with 
previous research conducted by Myers and Myers (2017). The author reported that when an 
individual experiences pain and is not able to communicate this distress, CB may emerge as a 
form of communication. Similarly, Charlot et al. (2011) examined non-psychiatric health 
concerns among individuals with dual diagnoses residing in in-patient settings. The authors 
indicated that physical distress arising from biomedical problems may increase CB. In the 
current study, the number of psychotropic medications was significantly correlated with the 
number of medical problems. Although the current study did not find a predictive relationship 
between medical diagnoses and the total number of psychotropic medications, pain was a 
significant predictor. Therefore, it is possible that individuals with ID with more pain 
communicated this distress with CB. This notion was further supported by the fact that pain was 
significantly correlated with aggression.  
The number of psychiatric diagnoses slightly predicted polypharmacy. Many studies 
suggested that mental health diagnoses predict psychotropic medication usage (Bowring et al., 
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2017a; Nottestad & Linaker, 2003; Tsiouris et al., 2013). Bowring et al. (2017a) reported that the 
presence of a psychiatric diagnosis predicted psychotropic medications in a generalised linear 
model. When Nottestad and Linaker (2003) conducted a stepwise regression, certain types of 
psychiatric disorders were significant predictors of the defined daily dosage of neuroleptic 
medications. In particular, adjustment and affective disorder increased psychotropic medication 
dosage (β = .21, p = .032; β = .21, p = .032, respectively). Lastly, Tsiouris et al. (2013) 
determined that bipolar and psychosis disorders were predictors associated with the use of 
antipsychotic, mood-stabilizer, and antianxiety medications. The presence of depression was also 
a significant predictor associated with using antidepressants. 
These previous findings aligned with the current study as psychiatric diagnoses predicted 
psychotropic medication. However, an analysis of specific psychiatric diagnoses as predictors, 
(e.g., the presence of schizophrenia) was not conducted in the current study. Although the DRS 
and NSS were used as potential predictors, these scales were not used as dichotomous variables 
that represented having a depression diagnosis or not. Perhaps analyzing the presence or absence 
of specific diagnoses may have revealed stronger relationships with psychotropic medication 
usage. The predictive relationship between psychiatric diagnoses and the total number of 
psychotropic medications suggested that psychotropic medications may have been appropriately 
prescribed to treat psychiatric conditions for a significant portion of the sample. It is possible that 
the transition planning and funding process for these study participants afforded them more 
access to health and mental health care than more recent population-based samples in Ontario. 
For example, Lunsky et al. (2017) recently reported that 28.91% of their sample of (N = 20,316) 
were prescribed antipsychotic medications without having a psychiatric diagnosis.  
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CB did not significantly predict the number of psychotropic medications in this model. 
These findings contradicted many studies that examined the influence of CB on psychotropic 
medication usage (Bowring et al., 2017a; Nottestad & Linaker, 2003; Robertson et al., 2000; 
Tsiouris et al., 2013). Nottestad and Linaker determined that CB was the most influential 
predictor of neuroleptic dosage. Similarly, Bowring et al. (2017a) found CB to be a significant 
predictor associated with psychotropic medication usage (RR = 1.565, p = .02). Certain classes of 
psychotropic medication have also been predicted by CB variables (Robertson et al., 2000). For 
instance, more CB (Aberrant Behaviour Checklist; ABC; Aman, Burrow, Wolford, 1995) was 
associated with the regular use (non-PRN) antipsychotic medication (Partial r = .1533, p < 
.0001) and antianxiety medication usage (Partial r = .2900, p < .0001). Similarly, Tsiouris et al. 
(2013) found aggression to be a significant predictor associated with antipsychotic, 
antidepressant, mood-convulsant, and antianxiety medications (p < .001).  
CB may not have predicted the total number of psychotropic medications due to the use 
of the ABS. CB is frequently measured by using the BPI (Bowring et al., 2017a; Bowring et al., 
2017b). In the current study, the ABS scale from the interRAI-ID was used to measure CB. 
Given the circumstances of the FI study, new data collection did not begin until C1, and the BPI 
was not used in the facility. The current study also examined a CB variable that was somewhat 
modeled after the BPI by adding up the number of CBs that were endorsed on the interRAI-ID. 
That variable was highly correlated with the ABS and would likely have produced similar 
findings to the ABS scale, so the scale was retained in the model. Post hoc analyses of the 
relationship between the BPI and the ABS at C1 were carried out to help to decipher this 
seemingly anomalous result. 
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 Post hoc analyses revealed that ABS may not have represented all types of CB. At C1, 
the BPI was not significantly correlated to the ABS. This finding indicated that the BPI and the 
ABS may have measured different aspects of CB. The BPI targeted aggression/destructive 
behaviour, SIB, and stereotypy while the ABS only measured aggression. A recent total 
population study found that of the 18.1% of individuals with ID engaged in CB, 10.9% and 7.5% 
of individuals with ID engaged in stereotyped and self-injurious behaviours (Bowring et al., 
2017b; N = 265). These types of CB were not captured by the ABS. It is possible that if the BPI 
was used to measure for CB rather than the ABS, CB may have predicted the number of 
psychotropic medications in the model. In this study, aggression did not predict the total number 
of psychotropic medications. In contrast to the current study, other researchers examined changes 
across specific classes of psychotropic medications, such as antipsychotic medications 
(Robertson et al., 2000; Tsiouris et al., 2013) or dosages of psychotropic medications (Nottestad 
& Linaker, 2003).  
Implications of the Findings  
 This study will add to the current breadth of research that examines psychotropic 
medication among former residents in Ontario. Many studies did not evaluate changes in 
outcomes of deinstitutionalization after the individuals had been living in the community for an 
extended period (McGillivray & McCabe, 2005; Nottestad & Linaker, 2003; Robertson et al., 
2000). By observing changes over time in the community, the field may better understand how 
former residents have adapted to the major life changes of deinstitutionalization. Despite over 50 
years of research, there are still jurisdictions providing institutional care. These findings lend 
support to previous research and policies recommending deinstitutionalization of individuals 
with ID and encourage other jurisdictions to embark on this process.  
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This study highlights the importance of conducting multivariate analyses to understand 
the influence of various characteristics on polypharmacy. Many variables that were significantly 
correlated with the total number of psychotropic medications, including aggression, adaptive 
functioning, and depression symptoms, did not predict polypharmacy in the final model. 
Although certain variables, such as aggression, may not have influenced polypharmacy due to 
measure limitations, the differences across statistical analyses should be noted. This study lends 
support to the continued use of multivariate analyses to understand predictors of polypharmacy 
rather than only investigating bivariate relationships. Secondly, the incorporation of a multilevel 
model ensures that the current study accounts for within-person variation while examining 
between-person changes.  
This study is impactful as it is the first multilevel model applied to examine psychotropic 
medication changes among individuals with ID who experienced deinstitutionalization. No 
studies to date were found that implemented a multilevel model to examine psychotropic 
medication usage among this group of individuals. Although other studies implemented 
multilevel analyses to examine psychotropic trends among individuals living in nursing homes 
(Mazieres, Lapeyre-Mestre, Vellas, Barreto, & Rolland, 2015; Sonntag, Matschinger, 
Angermeyer, & Riedell-Heller, 2005), these participants did not have ID diagnoses. Further, 
certain studies examined psychotropic medications with multilevel analyses among individuals 
with ASD, but only among children (Rubin, Feudtner, Localio, & Mandell, 2009). Therefore, 
this study expands the breadth of research examining psychotropic medication patterns among 
individuals with ID by accounting for both within and between- subject changes over time. This 
could be applied to treatment model by providing a longitudinal analysis across multiple points 
in time that compare an individual to the population level.  
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In addition to increasing the breadth of psychotropic medication research, applying this 
knowledge practically and clinically is important. Many studies emphasized that individuals with 
ID have a history of being prescribed multiple psychotropic medications (Sheehan et al., 2015; 
Sullivan et al., 2018). Individuals with ID face increased risk of side effects of psychotropic. 
Continually improving prescribing practices among individuals with ID is critical as individuals 
with ID may not always be able to advocate for prescribing practices changes (Sullivan et al., 
2018). This research provides evidence that can inform prescribing practices in Ontario by 
influencing physicians and policymakers’ decisions when treating individuals with ID. Specific 
consideration could be made towards individuals exhibiting characteristics that predict a higher 
number of psychotropic medications, such as worse health, pain and having more than one 
psychiatric diagnosis. This could include informing the revision of current guidelines as well as 
teaching physicians to recognize potential biases when working with individuals with ID. 
Health status variables, including health instability and pain, predicted psychotropic 
medication in this model. This finding indicated that for the overall model, as health instability 
worsened, the number of psychotropic medications increased. Similarly, as an individual 
experienced more pain, the number of psychotropic medications he or she received increased. It 
is critical that these health variables are considered as potential setting events for CB as the 
presence of certain symptoms could increase the likelihood that an individual engages in CB. For 
instance, Moss et al. (2005) reported that seven out of eight children with Cornelia de Lange 
syndrome exhibited self-injurious behaviour when certain setting events were present, such as 
extreme fatigue. Similarly, Carr et al. (2003) found menstrual discomfort to be a biological 
setting event for severe CB. These studies highlighted the importance of considering health 
variables when treating CB. 
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The impact of health issues on challenging behaviour is supported by Sullivan et al.’s 
(2018) guideline regarding CB. The authors stated that possible health problems should be 
considered when evaluating CB. To enhance these guidelines, individuals facing increased health 
risks and daily pain should have a higher frequency of check-ins with their physicians. Sullivan 
et al. (2018) indicated that reviews for medication usage should occur every three months. For 
individuals with health instability and daily pain, evaluating the influence of these psychotropic 
medications more frequently could ensure that these medications are not mismanaged and 
overprescribed to treat CB. Secondly, physicians should be trained to recognize this potential 
bias among individuals with ID. Emphasis should continue for evaluating biological causes of 
CB, such as pain and medical diagnoses, prior to prescribing psychotropic medications to 
manage these behaviour changes. These strategies align with the Behaviour Analyst Certification 
Board (BACB; 2014) Professional and Ethical Compliance Code, which stated that medical 
consultation should occur to rule out the possibility that biomedical conditions caused the CB. 
This strategy should be applied when physicians are treating CB, in that, health conditions and 
pain should be ruled out prior to prescribing psychotropic medications to reduce CB.  
Another important finding in this study was that the number of psychiatric diagnoses 
predicted the number of psychotropic medication usage. As psychiatric diagnoses increased, the 
number of psychotropic medications increased as well. Additionally, in C2, the number of 
psychotropic medications prescribed among individuals with more than one psychiatric diagnosis 
was widely distributed. Sullivan et al. (2018) described how psychiatric disorders should be 
screened continually by monitoring changes in behaviour and mental state. This screening 
process is particularly relevant for individuals with mental illness comorbidities as they could be 
prescribed psychotropic medication across different classes to treat multiple psychiatric 
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symptoms. As such, this group faces a risk of overmedication and side effects from 
polypharmacy combinations (Lunsky et al., 2017). However, Sullivan et al. (2018) did not 
provide specifics regarding how frequently these assessments should be conducted. Given that 
individuals with more than one diagnosis are more likely to receive large ranges of psychotropic 
medications than individuals with one diagnosis or no diagnoses, more consistent monitoring 
may be beneficial to ensure that medications are prescribed for treating psychiatric symptoms 
appropriately.  
This study emphasizes the importance of using the biopsychosocial approach when 
assessing and treating individuals with ID. This approach considers CB to be influenced by 
biological, psychological, and socioenvironmental factors (Gardner, Griffiths, & Hamelin, 2012). 
In the current study, health status variables, including health instability and pain, predicted the 
number of psychotropic medications. This finding could be directly linked to the biological 
component of the triad of the biopsychosocial model. It is possible that more pain or health 
conditions increased the likelihood that participants engaged in CB and as a result, led to 
increased psychotropic medications. Conversely, the number of psychiatric diagnoses and 
cognitive performance fall within the psychological component of the triad. Psychological 
variables that contribute to CB may include the excess of certain characteristics or a lack of 
central processing skills (Gardner et al., 2012). For instance, an individual with a schizophrenia 
diagnosis may respond differently to distress-producing conditions than an individual without 
that diagnosis. Although Sullivan et al. (2018) briefly mentioned the biopsychosocial approach, 
limited information is provided to help professionals conduct assessments within this model. 
Future prescribing policies may include additional information and training for physicians and 
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mental health professionals to teach them how to assess individuals with ID within the 
biopsychosocial model.  
The social component of the biopsychosocial triad relates to the environmental 
conditions, relationships, settings and other external variables that may influence CB. Behaviour 
analytic approaches focus on determining the function of CB and selecting corresponding 
treatments (Hanley, Iwata, & McCord, 2003). Research has found that the use of interventions 
based on the results of functional analyses were more predictive of successful outcomes than the 
specific type of behavioural intervention (National Institutes of Health, 1991), highlighting the 
importance of considering the function of CB when designing treatments. One such intervention 
includes functional communication training (FCT; Carr & Durand 1985). FCT is a function-
based procedure that uses differential reinforcement to teach appropriate communicative 
responses while extinguishing CB. FCT is a well-established intervention for CB among children 
with ID and or ASD and probably efficacious with adults (Kurtz et al., 2011). Although multiple 
researchers emphasized the importance of including function-based interventions during 
treatment (Gardner et al., 2012; Kurtz et al., 2011), psychotropic medications are frequently 
relied on despite not targeting the function of CB. In fact, Cox and Virues-Ortega (2015) 
determined that psychotropic medications might induce changes in the function of CB. 
Therefore, physicians and behaviour analysts should be wary of the risks related to the use of 
psychotropic medication in isolation. Behaviour analysts should also consider that polypharmacy 
may influence the function of CB and therefore, psychotropic medication changes could impact 
the effectiveness of behavioural interventions. As such, behaviour analysts need to work 
collaboratively with medical professionals to monitor the impact of medication on treatment 
effectiveness. 
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The findings of this study could be used to teach individuals with ID, their family 
members, and supports workers how to advocate for the most effective and least restrictive 
treatment. This is particularly important as Singh et al. (1996) emphasized that support staff and 
parents should be involved in decision making processes related to pharmacological intervention. 
Identifying individual characteristics that influence polypharmacy may help individuals with ID, 
family members, and support workers, understand the risk factors of polypharmacy. Sullivan et 
al. (2018) emphasized a person-centered approach when treating individuals with ID. The 
authors also discussed how to improve communication with patients and caregivers and that 
patients should be involved during primary care treatment. Although broad recommendations 
and tools were provided (e.g., Communicating Effectively tool), more thorough efforts could be 
made to involve clients and caregivers in the primary care process. This improved 
communication with individuals with ID is critical, especially considering the higher frequencies 
and large ranges of psychotropic medications among individuals with increased cognitive 
performance (e.g., intact to borderline intact).  
Sullivan et al. (2018)’s guidelines included educating the persons and caregivers about 
the appropriate use of medications. Therefore, an explanation of characteristics that may increase 
an individual’s risk of polypharmacy should be emphasized. Specific training could be provided 
to individuals with ID, caregivers, and support workers to ensure appropriate questions are asked 
when psychotropic medications are adjusted across an individual’s life span. For instance, this 
could involve using behavioural skills training to teach staff, family members and individuals 
with ID how to recognize risk factors and to ask appropriate questions during primary care visits. 
Potential questions to be asked may include “Have underlying medical conditions been ruled 
out?” or “Are we sure that he is not engaging in CB because he is in pain?”. Behavioural skills 
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training could be effective as this strategy has successfully been used to teach social and safety 
skills to adults with ID and other disabilities (Kornacki, Ringdahl, Sjostrom, & Nuerberger, 
2013; Miltenberger et al., 1999) and to train staff (Parsons, Rollyson, & Reid, 2012).  
Strengths  
 Strengths of this study lie in the sampling of the participants. This population consisted of 
individuals who previously lived in three different institutions across Ontario. As such, this study 
included participants that relocated from various institutions, which contrasts other 
deinstitutionalization studies (e.g., Nottestad & Linaker 1999; 2003). Further, when individuals 
transitioned to community settings, participants relocated to various locations in Ontario. 
Therefore, this representation across Ontario reduced sampling biases related to location and 
institutions.  
This study consisted of a multivariate analysis that examines predictors of psychotropic 
medication, which is a suggested method for improving current research regarding psychotropic 
medications among individuals with ID (Stortz et al., 2014). In particular, the use of a multilevel 
model that accounts for within-person variation while examining between-person change is a 
strength of the study. This is important because no studies to date have explored psychotropic 
medication patterns among individuals with ID following deinstitutionalization using this type of 
model (Mazieres et al., 2015; Rubin et al., 2009; Sonntag et al., 2005).  
Limitations 
Several limitations arose during the development and implementation of this study. 
Primarily, for a multilevel model to be conducted, the variables of interest have to be consistent 
over time. For F1, the only measure collected was the interRAI-ID. As such, to examine this 
model across these three points in time using a multilevel model, only measures found on the 
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interRAI-ID could be included. Incorporating other validated measures may have revealed more 
variables with predictive relationships with psychotropic medication usage. Secondly, direct 
comparisons could be more easily made when referring to other studies that examined 
psychotropic medication predictors (Bowring et al., 2017a; Robertson et al., 2000; Tsiouris et al., 
2003).  
Another limitation of this study was that the total number of psychotropic medications was 
chosen as the outcome variable, rather than other medication related variables such as dosage, 
medication class, or the correspondence between medication classes and diagnoses. Selecting 
dosages as an outcome measure may have provided a more thorough understanding regarding the 
relationship between individual characteristics, (e.g., health, CB, adaptive functioning), and 
psychotropic medication dosage (Nottestad & Linaker, 2003). Examining specific classes of 
psychotropic medications (e.g., antianxiety, antipsychotic, anticonvulsant) as the outcome 
measure may have yielded different relationships as well. Additionally, including the alignment 
between diagnoses and medication classes within the model might have strengthened the 
findings. Finally, it is noted the outcome variable was not the presence or absence of 
polypharmacy and therefore, specific conclusions relating to polypharmacy cannot be drawn. 
Other limitations arose when certain predictors were created by summing variables on the 
interRAI-ID. The total number of psychiatric diagnoses variable was created by adding the 
presence or absence of cognitive, mood, psychotic, and anxiety disorders. If a participant had 
more than one of these types of diagnoses (e.g., two anxiety diagnoses), this would be counted as 
only one diagnosis. Also, other disorders (e.g., trauma-related disorders, personality disorders) 
were not included. As such, this variable may have underestimated the number of mental health 
diagnoses for this population. Similarly, the total medical diagnoses variable consisted of 
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summing the presence or absence of certain health conditions to represent a summary of health 
status (i.e., asthma, cerebral palsy, diabetes mellitus, epilepsy or seizure disorder, 
hypothyroidism, and traumatic brain injury), however other health conditions were not included, 
potentially under representing the health needs of the sample. 
This sample was restricted to individuals with ID who were relocated from the facilities 
to communities in Ontario, therefore the results might not generalize to other community 
samples. The majority of measures used in this study were completed by proxy by support staff, 
as only a small number of individuals with ID in the sample had the requisite communication 
skills (Condillac et al., 2012). Though respondent had considerable experience in supporting the 
participant, they could have allowed biases to influence their responses. However, studying only 
those individuals with ID who had the skills to respond firsthand would leave a substantial 
portion of individuals with ID out of this research and would not have been representative of the 
individuals who were relocated as part of the Facilities Initiative. 
Future Steps 
 Future directions include considering other outcome variables related to psychotropic 
medication usage, such as classes of psychotropic medication, dosage values, or incidence rates. 
An additional outcome variable could include examining polypharmacy specifically by 
dichotomizing psychotropic medication usage into groups of individuals receiving two or more 
psychotropic medications and individuals receiving less than two medications. If data could be 
collected at an additional point in time, the richer measures (i.e., BPI, etc.) could be used to 
inform the model, rather than only the interRAI-ID. The use of these measures may also prove to 
be beneficial as more direct comparisons could be made across studies that implemented similar 
measures (Bowring et al., 2017a). Separating PRN and regular medications, rather than 
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examining these medications together, may be an effective future step in understanding 
differences in predictors for both types of psychotropic medications. Further, considering the 
influence of general medications (non-psychotropic medication) could enhance the model of 
overall medication usage among individuals with ID. Lastly, this study included the last point in 
time for the facility for participants. Access to interRAI-ID data is available from all individuals 
who remained in the facilities from 2005 to 2008, and therefore, multiple data points within the 
institution are available for some participants. By incorporating these additional points of time 
into a multilevel analysis, a more thorough analysis of psychotropic medication changes over 
time could be obtained.  
Summary and Conclusions 
In this study, a multilevel model revealed that the number of psychotropic medications 
decreased as individuals adjusted to living in their new communities. Cognitive performance, 
mental health status, pain and health conditions predicted the total number of psychotropic 
medications. However, the influence of worse health on the number of psychotropic medications 
changed as individuals transitioned into community settings. Understanding these predictors of 
medication usage may help policy makers to develop or revise recommendations and guidelines 
and could potentially inform prescribing practices among physicians. The knowledge of risk 
factors can also be conveyed to individuals with ID and their caregivers. With this knowledge, 
family members, support agencies, and individuals with ID may increase their abilities to 
advocate for changes and improvements in psychotropic medication management. Lastly, despite 
the evidence of improved outcomes following deinstitutionalization, jurisdictions continue to 
care for individuals with ID in institutional settings. This study contributes to the body of 
research supporting the deinstitutionalization of individuals with ID by emphasizing the 
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improvements in psychotropic medication management among individuals who relocated from 
facility to community settings in Ontario.  
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